

REFINITIV

DELTA REPORT

10-Q

SMPL - SIMPLY GOOD FOODS CO
10-Q - NOVEMBER 25, 2023 COMPARED TO 10-Q - MAY 27, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	511
<div>CHANGES</div>	179
<div>DELETIONS</div>	203
<div>ADDITIONS</div>	129

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended May 27, 2023 November 25, 2023

OR


☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-38115

The Simply Good Foods Company

(Exact name of registrant as specified in its charter)



Delaware

82-1038121

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer Identification No.)

1225 17th Street, Suite 1000

Denver, CO 80202

(Address of principal executive offices and zip code)

(303) 633-2840

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	SMPL	Nasdaq

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of [June 26, 2023](#) [December 26, 2023](#), there were [99,548,989](#) [99,812,510](#) shares of common stock, par value \$0.01 per share, issued and outstanding.

THE SIMPLY GOOD FOODS COMPANY AND SUBSIDIARIES
FORM 10-Q
FOR THE QUARTER ENDED [MAY 27, NOVEMBER 25, 2023](#)

INDEX

	Page
PART I. Financial Information	
Item 1.	Financial Statements (Unaudited)
	3
	Consolidated Balance Sheets
	3
	Consolidated Statements of Operations and Comprehensive Income
	4
	Consolidated Statements of Cash Flows
	5
	Consolidated Statements of Stockholders' Equity
	7
	Notes to Unaudited Consolidated Financial Statements
	9 8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations
	20 18
Item 3.	Quantitative and Qualitative Disclosures about Market Risk
	30 26
Item 4.	Controls and Procedures
	30 26
PART II. Other Information	
Item 1.	Legal Proceedings
	31 27
Item 1A.	Risk Factors
	31 27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds
	31 27
Item 3.	Defaults Upon Senior Securities
	31 27
Item 4.	Mine Safety Disclosures
	31 27
Item 5.	Other Information
	31 27
Item 6.	Exhibits
	32 28
	Signatures
	33 29

PART I. Financial Information

Item 1. Financial Statements (Unaudited)

The Simply Good Foods Company and Subsidiaries
Consolidated Balance Sheets
(Unaudited, dollars in thousands, except share and per share data)

		May 27, 2023	August 27, 2022		November 25, 2023	August 26, 2023
Assets	Assets			Assets		
Current assets:	Current assets:			Current assets:		
Cash	Cash	\$ 68,794	\$ 67,494	Cash	\$ 121,391	\$ 87,715
Accounts receivable, net	Accounts receivable, net	145,430	132,667	Accounts receivable, net	135,561	145,078
Inventories	Inventories	105,437	125,479	Inventories	123,175	116,591
Prepaid expenses	Prepaid expenses	5,759	5,027	Prepaid expenses	6,076	6,294
Other current assets	Other current assets	24,390	20,934	Other current assets	10,336	15,974
Total current assets	Total current assets	349,810	351,601	Total current assets	396,539	371,652
Long-term assets:	Long-term assets:			Long-term assets:		
Property and equipment, net	Property and equipment, net	24,414	18,157	Property and equipment, net	23,830	24,861
Intangible assets, net	Intangible assets, net	1,111,865	1,123,258	Intangible assets, net	1,104,318	1,108,119
Goodwill	Goodwill	543,134	543,134	Goodwill	543,134	543,134
Other long-term assets	Other long-term assets	50,778	58,099	Other long-term assets	47,238	49,318

Total assets	Total assets	\$2,080,001	\$2,094,249	Total assets	\$2,115,059	\$2,097,084
Liabilities and stockholders' equity	Liabilities and stockholders' equity			Liabilities and stockholders' equity		
Current liabilities:	Current liabilities:			Current liabilities:		
Accounts payable	Accounts payable	\$ 45,867	\$ 62,149	Accounts payable	\$ 43,249	\$ 52,712
Accrued interest	Accrued interest	43	160	Accrued interest	1,574	1,940
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	25,166	39,675	Accrued expenses and other current liabilities	34,083	35,062
Current maturities of long-term debt	Current maturities of long-term debt	199	264	Current maturities of long-term debt	83	143
Total current liabilities	Total current liabilities	71,275	102,248	Total current liabilities	78,989	89,857
Long-term liabilities:	Long-term liabilities:			Long-term liabilities:		
Long-term debt, less current maturities	Long-term debt, less current maturities	320,900	403,022	Long-term debt, less current maturities	272,032	281,649
Deferred income taxes	Deferred income taxes	117,281	105,676	Deferred income taxes	120,200	116,133
Other long-term liabilities	Other long-term liabilities	39,727	44,639	Other long-term liabilities	36,660	38,346
Total liabilities	Total liabilities	549,183	655,585	Total liabilities	507,881	525,985
See commitments and contingencies (Note 9)	See commitments and contingencies (Note 9)			See commitments and contingencies (Note 9)		
Stockholders' equity:	Stockholders' equity:			Stockholders' equity:		
Preferred stock, \$0.01 par value, 100,000,000 shares authorized, none issued	Preferred stock, \$0.01 par value, 100,000,000 shares authorized, none issued	—	—	Preferred stock, \$0.01 par value, 100,000,000 shares authorized, none issued	—	—
Common stock, \$0.01 par value, 600,000,000 shares authorized, 101,912,526 and 101,322,834 shares issued at May 27, 2023 and August 27, 2022, respectively	Common stock, \$0.01 par value, 600,000,000 shares authorized, 101,912,526 and 101,322,834 shares issued at May 27, 2023 and August 27, 2022, respectively	1,019	1,013	Common stock, \$0.01 par value, 600,000,000 shares authorized, 102,175,233 and 101,929,868 shares issued at November 25, 2023 and August 26, 2023, respectively	1,022	1,019
Treasury stock, 2,365,100 shares and 1,818,754 shares at cost at May 27, 2023 and August 27, 2022, respectively	Treasury stock, 2,365,100 shares and 1,818,754 shares at cost at May 27, 2023 and August 27, 2022, respectively	(78,451)	(62,003)	Treasury stock, 2,365,100 shares and 2,365,100 shares at cost at November 25, 2023 and August 26, 2023, respectively	(78,451)	(78,451)
Additional paid-in-capital	Additional paid-in-capital	1,299,318	1,287,224	Additional paid-in-capital	1,303,411	1,303,168
Retained earnings	Retained earnings	311,314	214,381	Retained earnings	383,517	347,956
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(2,382)	(1,951)	Accumulated other comprehensive loss	(2,321)	(2,593)
Total stockholders' equity	Total stockholders' equity	1,530,818	1,438,664	Total stockholders' equity	1,607,178	1,571,099
Total liabilities and stockholders' equity	Total liabilities and stockholders' equity	\$2,080,001	\$2,094,249	Total liabilities and stockholders' equity	\$2,115,059	\$2,097,084

See accompanying notes to the unaudited consolidated financial statements.

The Simply Good Foods Company and Subsidiaries
Consolidated Statements of Operations and Comprehensive Income
(Unaudited, dollars in thousands, except share and per share data)

		Thirteen Weeks Ended		Thirty-Nine Weeks Ended			Thirteen Weeks Ended	
		May 27, 2023	May 28, 2022	May 27, 2023	May 28, 2022		November 25, 2023	November 26, 2022
Net sales	Net sales	\$ 324,792	\$ 316,531	\$ 922,254	\$ 894,514	Net sales	\$ 308,678	\$ 300,878
Cost of goods sold	Cost of goods sold	205,546	197,883	589,284	550,788	Cost of goods sold	193,560	189,886
Gross profit	Gross profit	119,246	118,648	332,970	343,726	Gross profit	115,118	110,992
Operating expenses:	Operating expenses:					Operating expenses:		

Selling and marketing	Selling and marketing	30,168	32,334	88,650	94,816	Selling and marketing	31,990	28,534
General and administrative	General and administrative	30,510	26,721	82,085	76,711	General and administrative	26,950	25,641
Depreciation and amortization	Depreciation and amortization	4,363	4,317	13,035	12,966	Depreciation and amortization	4,358	4,327
Total operating expenses	Total operating expenses	65,041	63,372	183,770	184,493	Total operating expenses	63,298	58,502
Income from operations	Income from operations	54,205	55,276	149,200	159,233	Income from operations	51,820	52,490
Other income (expense):	Other income (expense):					Other income (expense):		
Interest income	Interest income	407	—	660	1	Interest income	1,090	7
Interest expense	Interest expense	(7,649)	(4,881)	(23,201)	(16,528)	Interest expense	(6,034)	(7,055)
Loss in fair value change of warrant liability		—	—	—	(30,062)			
Gain on foreign currency transactions	Gain on foreign currency transactions	180	76	74	503	Gain on foreign currency transactions	226	108
Other income	Other income	4	17	10	26	Other income	6	6
Total other expense	Total other expense	(7,058)	(4,788)	(22,457)	(46,060)	Total other expense	(4,712)	(6,934)
Income before income taxes	Income before income taxes	47,147	50,488	126,743	113,173	Income before income taxes	47,108	45,556
Income tax expense	Income tax expense	11,716	11,654	29,810	34,726	Income tax expense	11,547	9,696
Net income	Net income	\$ 35,431	\$ 38,834	\$ 96,933	\$ 78,447	Net income	\$ 35,561	\$ 35,860
Other comprehensive income:	Other comprehensive income:					Other comprehensive income:		
Foreign currency translation, net of reclassification adjustments	Foreign currency translation, net of reclassification adjustments	(262)	(72)	(431)	(820)	Foreign currency translation, net of reclassification adjustments	272	(222)
Comprehensive income	Comprehensive income	\$ 35,169	\$ 38,762	\$ 96,502	\$ 77,627	Comprehensive income	\$ 35,833	\$ 35,638
Earnings per share from net income:	Earnings per share from net income:					Earnings per share from net income:		
Basic	Basic	\$ 0.36	\$ 0.39	\$ 0.98	\$ 0.80	Basic	\$ 0.36	\$ 0.36
Diluted	Diluted	\$ 0.35	\$ 0.38	\$ 0.96	\$ 0.78	Diluted	\$ 0.35	\$ 0.36
Weighted average shares outstanding:	Weighted average shares outstanding:					Weighted average shares outstanding:		
Basic	Basic	99,518,546	100,426,227	99,404,174	98,294,114	Basic	99,629,188	99,200,557
Diluted	Diluted	100,909,972	102,237,457	100,847,970	100,190,068	Diluted	101,094,736	100,723,036

See accompanying notes to the unaudited consolidated financial statements.

The Simply Good Foods Company and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited, dollars in thousands)

		Thirty-Nine Weeks Ended		Thirteen Weeks Ended	
		May 27, 2023	May 28, 2022	November 25, 2023	November 26, 2022
Operating activities	Operating activities				
Net income	Net income	\$96,933	\$78,447	\$ 35,561	\$ 35,860
Adjustments to reconcile net income to net cash provided by operating activities:	Adjustments to reconcile net income to net cash provided by operating activities:				
Depreciation and amortization	Depreciation and amortization	15,044	14,398	5,605	4,952
Amortization of deferred financing costs and debt discount	Amortization of deferred financing costs and debt discount	2,011	2,073	385	532
Stock compensation expense	Stock compensation expense	10,456	8,691	4,168	3,313
Change in fair value change of warrant liability		—	30,062		
Estimated credit losses	Estimated credit losses	206	148	51	(141)
Unrealized loss (gain) on foreign currency transactions		(74)	(503)		

Unrealized gain on foreign currency transactions				Unrealized gain on foreign currency transactions	
Deferred income taxes	Deferred income taxes	11,696	14,140	Deferred income taxes	(226) (108)
Amortization of operating lease right-of-use asset	Amortization of operating lease right-of-use asset	5,018	4,955	Amortization of operating lease right-of-use asset	4,084 3,206
Gain on lease termination		—	(30)		
Other	Other	759	345	Other	1,735 1,660
Changes in operating assets and liabilities:	Changes in operating assets and liabilities:			Changes in operating assets and liabilities:	
Accounts receivable, net	Accounts receivable, net	(13,334)	(35,269)	Accounts receivable, net	9,869 (26,288)
Inventories	Inventories	19,444	(15,006)	Inventories	(6,699) 638
Prepaid expenses	Prepaid expenses	(745)	(170)	Prepaid expenses	257 (541)
Other current assets	Other current assets	(1,595)	(37,288)	Other current assets	5,173 8,631
Accounts payable	Accounts payable	(16,115)	5,585	Accounts payable	(9,806) (6,609)
Accrued interest	Accrued interest	(117)	154	Accrued interest	(366) 97
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	(15,030)	676	Accrued expenses and other current liabilities	(1,337) (14,843)
Other assets and liabilities	Other assets and liabilities	(4,145)	(4,045)	Other assets and liabilities	(1,232) (2,212)
Net cash provided by operating activities	Net cash provided by operating activities	110,412	67,363	Net cash provided by operating activities	47,523 8,718
Investing activities	Investing activities			Investing activities	
Purchases of property and equipment	Purchases of property and equipment	(10,108)	(4,696)	Purchases of property and equipment	(744) (1,151)
Issuance of note receivable		—	(2,400)		
Investments in intangible and other assets	Investments in intangible and other assets	(338)	(187)	Investments in intangible and other assets	(56) (87)
Net cash used in investing activities	Net cash used in investing activities	(10,446)	(7,283)	Net cash used in investing activities	(800) (1,238)
Financing activities	Financing activities			Financing activities	
Proceeds from option exercises	Proceeds from option exercises	5,035	4,343	Proceeds from option exercises	— 4,563
Tax payments related to issuance of restricted stock units and performance stock units	Tax payments related to issuance of restricted stock units and performance stock units	(2,755)	(3,536)	Tax payments related to issuance of restricted stock units and performance stock units	(3,642) (2,298)
Payments on finance lease obligations	Payments on finance lease obligations	(217)	(235)	Payments on finance lease obligations	(61) (78)
Cash received on repayment of note receivable				Cash received on repayment of note receivable	600 —
Repurchase of common stock	Repurchase of common stock	(16,448)	(28,504)	Repurchase of common stock	— (16,448)
Principal payments of long-term debt	Principal payments of long-term debt	(81,500)	(50,000)	Principal payments of long-term debt	(10,000) (6,500)
Deferred financing costs		(2,694)	(544)		
Net cash used in financing activities	Net cash used in financing activities	(98,579)	(78,476)	Net cash used in financing activities	(13,103) (20,761)
Cash and cash equivalents	Cash and cash equivalents			Cash and cash equivalents	
Net increase (decrease) in cash	Net increase (decrease) in cash	1,387	(18,396)	Net increase (decrease) in cash	33,620 (13,281)
Effect of exchange rate on cash	Effect of exchange rate on cash	(87)	(229)	Effect of exchange rate on cash	56 (69)
Cash at beginning of period	Cash at beginning of period	67,494	75,345	Cash at beginning of period	87,715 67,494
Cash and cash equivalents at end of period	Cash and cash equivalents at end of period	\$68,794	\$56,720	Cash and cash equivalents at end of period	\$ 121,391 \$ 54,144

		Thirty-Nine Weeks Ended		Thirteen Weeks Ended	
		May 27, 2023	May 28, 2022	November 25, 2023	November 26, 2022
Supplemental disclosures of cash flow information	Supplemental disclosures of cash flow information				
Cash paid for interest	Cash paid for interest	\$ 21,295	\$ 14,301	Cash paid for interest	\$ 2,135 \$ 6,426
Cash paid for taxes	Cash paid for taxes	\$ 19,542	\$ 43,430	Cash paid for taxes	\$ 628 \$ 8
Non-cash investing and financing transactions	Non-cash investing and financing transactions				
Issuance of common stock in extinguishment of warrant liabilities		\$ —	\$ 189,897		
Operating lease right-of-use assets exchanged for operating lease liabilities		\$ —	\$ 6,881		

Non-cash credits for repayment of note receivable	Non-cash credits for repayment of note receivable	\$	221	\$	—	Non-cash credits for repayment of note receivable	\$	229	\$	—
Non-cash additions to property and equipment						Non-cash additions to property and equipment	\$	99	\$	—
Non-cash additions to intangible assets	Non-cash additions to intangible assets	\$	120	\$	—	Non-cash additions to intangible assets	\$	75	\$	53

See accompanying notes to the unaudited consolidated financial statements.

The Simply Good Foods Company and Subsidiaries
Consolidated Statements of Stockholders' Equity
(Unaudited, dollars in thousands, except share data)

		Common Stock		Treasury Stock		Additional	Retained	Accumulated	Total	Common Stock			Treas
		Shares	Amount	Shares	Amount	Paid-In Capital	Earnings	Other Comprehensive Loss		Amount	Shares	Amount	
Balance at August 27, 2022		101,322,834	\$1,013	1,818,754	\$(62,003)	\$1,287,224	\$214,381	\$ (1,951)	\$1,438,664				
Balance at August 26, 2023										Balance at August 26, 2023			
										101,929,868	\$ 1,019	2,365,1	
Net income	Net income	—	—	—	—	—	35,860	—	35,860	Net income	—	—	
Stock-based compensation	Stock-based compensation	—	—	—	—	3,237	—	—	3,237	Stock-based compensation	—	—	
Foreign currency translation adjustments	Foreign currency translation adjustments	—	—	—	—	—	—	(222)	(222)	Foreign currency translation adjustments	—	—	
Repurchase of common stock	Repurchase of common stock	—	—	546,346	(16,448)	—	—	—	(16,448)	Repurchase of common stock	—	—	
Shares issued upon vesting of restricted stock units and performance stock units	Shares issued upon vesting of restricted stock units and performance stock units	180,342	2	—	—	(2,300)	—	—	(2,298)	Shares issued upon vesting of restricted stock units and performance stock units	245,365	3	
Exercise of options and stock appreciation rights to purchase common stock		353,281	4	—	—	4,559	—	—	4,563				
Balance at November 26, 2022		101,856,457	\$1,019	2,365,100	\$(78,451)	\$1,292,720	\$250,241	\$ (2,173)	\$1,463,356				
Net income		—	—	—	—	—	25,642	—	25,642				
Stock-based compensation		—	—	—	—	2,739	—	—	2,739				
Foreign currency translation adjustments		—	—	—	—	—	—	53	53				
Exercise of options to purchase common stock										Exercise of options to purchase common stock	—	—	
Shares issued upon vesting of restricted stock units		4,584	—	—	—	(103)	—	—	(103)				
Exercise of options to purchase common stock		12,130	—	—	—	228	—	—	228				
Balance at February 25, 2023		101,873,171	\$1,019	2,365,100	(78,451)	1,295,584	\$275,883	(2,120)	1,491,915				

Net income	—	—	—	—	—	\$ 35,431	—	35,431
Stock-based compensation	—	—	—	—	3,844	—	—	3,844
Foreign currency translation adjustments	—	—	—	—	—	—	(262)	(262)
Shares issued upon vesting of restricted stock units	18,960	1	—	—	(355)	—	—	(354)
Exercise of options to purchase common stock	20,395	(1)	—	—	245	—	—	244
Balance at May 27, 2023	101,912,526	1,019	2,365,100	(78,451)	1,299,318	311,314	(2,382)	1,530,818
Balance at November 25, 2023								Balance at November 25, 2023
								102,175,233
								1,022
								2,365,1

	Common Stock		Treasury Stock		Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
	Shares	Amount	Shares	Amount				
Balance at August 28, 2021	95,882,908	\$ 959	98,234	\$ (2,145)	\$ 1,085,001	\$ 105,807	\$ (818)	\$ 1,188,804
Net income	—	—	—	—	—	21,152	—	21,152
Stock-based compensation	—	—	—	—	2,605	—	—	2,605
Foreign currency translation adjustments	—	—	—	—	—	—	(40)	(40)
Shares issued upon vesting of restricted stock units and performance stock units	227,729	2	—	—	(3,190)	—	—	(3,188)
Exercise of options to purchase common stock	19,804	—	—	—	274	—	—	274
Warrant conversion	—	—	—	—	—	—	—	—
Balance at November 27, 2021	96,130,441	\$ 961	98,234	\$ (2,145)	\$ 1,084,690	\$ 126,959	\$ (858)	\$ 1,209,607
Net income	—	—	—	—	—	18,461	—	18,461
Stock-based compensation	—	—	—	—	3,092	—	—	3,092
Foreign currency translation adjustments	—	—	—	—	—	—	439	439
Reclassification adjustment for currency translation gains related to the liquidation of foreign entities	—	—	—	—	—	—	(1,147)	(1,147)
Repurchase of common stock	—	—	571,521	(20,394)	—	—	—	(20,394)
Warrant conversion	4,830,761	48	—	—	189,849	—	—	189,897
Shares issued upon vesting of restricted stock units	9,679	1	—	—	(102)	—	—	(101)
Exercise of options to purchase common stock	100,000	1	—	—	1,199	—	—	1,200
Balance at February 26, 2022	101,070,881	1,011	669,755	(22,539)	1,278,728	145,420	(1,566)	1,401,054
Net income	—	—	—	—	—	38,834	—	38,834
Stock-based compensation	—	—	—	—	2,994	—	—	2,994
Repurchase of common stock	—	—	218,221	(8,110)	—	—	—	(8,110)
Foreign currency translation adjustments	—	—	—	—	—	—	(72)	(72)
Shares issued upon vesting of restricted stock units	11,358	—	—	—	(247)	—	—	(247)
Exercise of options to purchase common stock	232,987	2	—	—	2,867	—	—	2,869
Balance at May 28, 2022	101,315,226	1,013	887,976	(30,649)	1,284,342	184,254	(1,638)	1,437,322

	Common Stock		Treasury Stock		Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
	Shares	Amount	Shares	Amount				
Balance at August 27, 2022	101,322,834	\$ 1,013	1,818,754	\$ (62,003)	\$ 1,287,224	\$ 214,381	\$ (1,951)	\$ 1,438,664
Net income	—	—	—	—	—	35,860	—	35,860
Stock-based compensation	—	—	—	—	3,237	—	—	3,237
Repurchase of Common Stock	—	—	546,346	(16,448)	—	—	—	(16,448)
Foreign currency translation adjustments	—	—	—	—	—	—	(222)	(222)
Shares issued upon vesting of restricted stock units and performance stock units	180,342	2	—	—	(2,300)	—	—	(2,298)
Exercise of options and stock appreciation rights to purchase common stock	353,281	4	—	—	4,559	—	—	4,563
Balance at November 26, 2022	101,856,457	1,019	2,365,100	(78,451)	1,292,720	250,241	(2,173)	1,463,356

See accompanying notes to the unaudited consolidated financial statements.

Notes to Unaudited Consolidated Financial Statements
(Unaudited, dollars in thousands, except for share and per share data)

1. Nature of Operations and Principles of Consolidation

Description of Business

The Simply Good Foods Company ("Simply Good Foods" or the "Company") is a consumer packaged food and beverage company that aims to lead the nutritious snacking movement with trusted brands that offer a variety of convenient, innovative, great-tasting, better-for-you snacks and meal replacements, and other product offerings. The product portfolio the Company develops, markets and sells consists primarily of protein bars, ready-to-drink ("RTD") shakes, sweet and salty snacks and confectionery products marketed under the **Atkins®**, **Atkins Endulge®**, **Quest®** and **Quest Hero™** **Atkins®** brand names. Simply Good Foods is poised to expand its wellness platform through innovation and organic growth along with acquisition opportunities in the nutritional snacking space.

The Company's nutritious snacking platform consists of brands that specialize in providing products for consumers that follow certain nutritional philosophies and health-and-wellness trends: **Atkins® for those following a low-carb lifestyle and Quest® for consumers seeking a variety of protein-rich foods and beverages that also limit sugars and simple carbs, carbs and Atkins® for those following a low-carb lifestyle.** The Company distributes its products in major retail channels, primarily in North America, including grocery, club, and mass merchandise, as well as through e-commerce, convenience, specialty, and other channels. The Company's portfolio of nutritious snacking brands gives it a strong platform with which to introduce new products, expand distribution, and attract new consumers to its products.

The common stock of Simply Good Foods is listed on the Nasdaq Capital Market under the symbol "SMPL."

Unaudited Interim Consolidated Financial Statements

The unaudited interim consolidated financial statements include the accounts of Simply Good Foods and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. Unless the context otherwise requires, "we," "us," "our" and the "Company" refer to Simply Good Foods and its subsidiaries.

The Company maintains its accounting records on a 52/53-week fiscal year, ending on the last Saturday in August of each year.

The interim consolidated financial statements and related notes of the Company and its subsidiaries are unaudited. The unaudited interim consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP") and the rules and regulations of the Securities and Exchange Commission (the "SEC"). The unaudited interim consolidated financial statements reflect all adjustments and disclosures which are, in the Company's opinion, necessary for a fair presentation of the results of operations, financial position and cash flows for the indicated periods. All such adjustments were of a normal and recurring nature unless otherwise disclosed. The year-end balance sheet data was derived from the audited financial statements and, in accordance with the instructions to Form 10-Q, certain information and footnote disclosures required by GAAP have been condensed or omitted. The results reported in these unaudited interim consolidated financial statements are not necessarily indicative of the results that may be reported for the entire fiscal year and should be read in conjunction with the Company's consolidated financial statements for the fiscal year ended **August 27, 2022** **August 26, 2023**, included in the Company's Annual Report on Form 10-K ("Annual Report") filed with the SEC on **October 21, 2022** **October 24, 2023**.

The ultimate effect the supply chain challenges, cost pressures, current high inflation environment, and the possible economic recession could have on consumer purchasing patterns and on the Company's business continues to be not fully known. Additionally, management is continuing to monitor the conflict in Ukraine, especially regarding the

availability and cost of raw materials that are produced in this region and Europe in general. Management is also monitoring the situation in Eastern Europe for its possible supply chain and consumer consumption effects on the Company's business.

2. Summary of Significant Accounting Policies

Refer to Note 2, *Summary of Significant Accounting Policies*, to the consolidated financial statements included in the Annual Report for a description of significant accounting policies.

Recently Issued and Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted

In March 2020, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting ("ASU 2020-04"), which provides optional guidance for a limited period of time to ease the potential burden in accounting for reference rate reform on financial reporting. Additionally, in December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848), Deferral of the Sunset Date of Topic 848, which extended the period of time for which ASU 2020-04 could be applied. As a result, the amendments in ASU 2020-04 can be applied to contract modifications due to rate reform and eligible existing and new hedging relationships entered into between March 12, 2020 and December 31, 2024. The amendments of these ASUs are effective for all entities and ~~should be~~ are applied on a prospective basis.

On January 21, 2022, the Company entered into a repricing amendment (the "2022 Repricing Amendment") to its credit agreement with Barclays Bank PLC and other parties (as amended to date, the "Credit Agreement"), as described in Note 5, Long-Term Debt and Line of Credit. In addition to replacing the London Interbank Offered Rate ("LIBOR") as the Credit Agreement's reference rate with the Secured Overnight Financing Rate ("SOFR"), the 2022 Repricing Amendment contemporaneously modified other terms that changed, or had the potential to change, the amount or timing of contractual cash flows as contemplated by the guidance in ASU 2020-04. As such, the contract modifications related to the 2022 Repricing Amendment were outside of the scope of the optional guidance in ASU 2020-04. The Company will continue to monitor the effects of rate reform, if any, on any new or amended contracts through December 31, 2024. The Company does not anticipate the amendments in this ASU will be material to its consolidated financial statements.

In November 2023, the Financial Accounting Standards Board ("FASB") issues Accounting Standard Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the provisions of the amendments and the effect on its future consolidated financial statements.

No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material effect on the Company's consolidated financial statements.

3. Revenue Recognition

Revenue from transactions with external customers for each of the Company's products would be impracticable to disclose and management does not view its business by product line. The following is a summary of revenue disaggregated by geographic area and brands:

(In thousands)	(In thousands)	Thirteen Weeks Ended		Thirty-Nine Weeks Ended		(In thousands)	Thirteen Weeks Ended	
		May 27, 2023	May 28, 2022	May 27, 2023	May 28, 2022		November 25, 2023	November 26, 2022
North America ⁽¹⁾	North America ⁽¹⁾					North America ⁽¹⁾		
Atkins	Atkins	\$ 142,057	\$ 148,163	\$ 408,153	\$ 417,539	Atkins	\$ 119,498	\$ 131,745
Quest	Quest	174,477	160,261	490,547	451,128	Quest	181,463	161,472
Total North America	Total North America	316,534	308,424	898,700	868,667	Total North America	300,961	293,217
International	International	8,258	8,107	23,554	25,847	International	7,717	7,661
Total net sales	Total net sales	\$ 324,792	\$ 316,531	\$ 922,254	\$ 894,514	Total net sales	\$ 308,678	\$ 300,878

⁽¹⁾ The North America geographic area consists of net sales substantially related to the United States and there is no individual foreign country to which more than 10% of the Company's net sales are attributed or that is otherwise deemed individually material.

Charges related to credit loss on accounts receivables from transactions with external customers were \$0.2 million and \$0.4 million for the thirteen and thirty-nine weeks ended May 27, 2023, respectively. Charges related to credit loss on accounts receivables from transactions with external customers were \$0.2 million and \$0.1 million for the thirteen and thirty-nine weeks ended May 28, 2022 November 25, 2023, respectively, and \$(0.1) million for the thirteen weeks ended November 26, 2022. As of May 27, 2023 November 25, 2023 and August 27, 2022 August 26, 2023, the allowances for doubtful accounts related to these accounts receivable were \$1.8 \$0.9 million and \$1.2 \$1.1 million, respectively. Additionally, as of May 27, 2023 November 25, 2023, the Company had an expected credit loss reserve of \$1.0 million on a \$3.0 million note receivable related to the Company's sale of its SimplyProtein® brand and related assets during its fiscal year 2021.

4. Goodwill and Intangibles

As of [May 27, 2023](#) [November 25, 2023](#) and [August 27, 2022](#) [August 26, 2023](#), Goodwill in the Consolidated Balance Sheets was \$543.1 million. There were no impairment charges related to goodwill during the thirteen [and thirty-nine](#) weeks ended [May 27, 2023](#) [November 25, 2023](#) or since the inception of the Company.

Intangible assets, net in the Consolidated Balance Sheets consists of the following:

(In thousands)	(In thousands)	Useful life	May 27, 2023			(In thousands)	Useful life	November 25, 2023		
			Gross carrying amount	Accumulated amortization	Net carrying amount			Gross carrying amount	Accumulated amortization	Net carrying amount
Intangible assets with indefinite life:	Intangible assets with indefinite life:					Intangible assets with indefinite life:				
		Indefinite					Indefinite			
Brands and trademarks	Brands and trademarks	life	\$ 974,000	\$ —	\$ 974,000	Brands and trademarks	life	\$ 974,000	\$ —	\$ 974,000
Intangible assets with finite lives:	Intangible assets with finite lives:					Intangible assets with finite lives:				
Customer relationships	Customer relationships	15 years	174,000	50,403	123,597	Customer relationships	15 years	174,000	56,203	117,797
Licensing agreements	Licensing agreements	13 years	22,000	10,019	11,981	Licensing agreements	13 years	22,000	10,977	11,023
Proprietary recipes and formulas	Proprietary recipes and formulas	7 years	7,000	5,881	1,119	Proprietary recipes and formulas	7 years	7,000	6,381	619
Software and website development costs	Software and website development costs	5 3 - years	6,022	5,068	954	Software and website development costs	5 3 - years	6,328	5,633	695
Intangible assets in progress	Intangible assets in progress	5 3 - years	214	—	214	Intangible assets in progress	5 3 - years	184	—	184
			<u>\$ 1,183,236</u>	<u>\$ 71,371</u>	<u>\$ 1,111,865</u>			<u>\$ 1,183,512</u>	<u>\$ 79,194</u>	<u>\$ 1,104,318</u>
(In thousands)	(In thousands)	Useful life	August 27, 2022			(In thousands)	Useful life	August 26, 2023		
			Gross carrying amount	Accumulated amortization	Net carrying amount			Gross carrying amount	Accumulated amortization	Net carrying amount
Intangible assets with indefinite life:	Intangible assets with indefinite life:					Intangible assets with indefinite life:				
		Indefinite					Indefinite			
Brands and trademarks	Brands and trademarks	life	\$ 974,000	\$ —	\$ 974,000	Brands and trademarks	life	\$ 974,000	\$ —	\$ 974,000
Intangible assets with finite lives:	Intangible assets with finite lives:					Intangible assets with finite lives:				
Customer relationships	Customer relationships	15 years	174,000	41,703	132,297	Customer relationships	15 years	174,000	53,303	120,697
Licensing agreements	Licensing agreements	13 years	22,000	8,581	13,419	Licensing agreements	13 years	22,000	10,498	11,502
Proprietary recipes and formulas	Proprietary recipes and formulas	7 years	7,000	5,131	1,869	Proprietary recipes and formulas	7 years	7,000	6,131	869
Software and website development costs	Software and website development costs	5 3 - years	5,863	4,190	1,673	Software and website development costs	5 3 - years	6,328	5,356	972
Intangible assets in progress	Intangible assets in progress	5 3 - years				Intangible assets in progress	5 3 - years	79	—	79
			<u>\$ 1,183,407</u>	<u>\$ 75,288</u>	<u>\$ 1,108,119</u>					
			<u>\$ 1,182,863</u>	<u>\$ 59,605</u>	<u>\$ 1,123,258</u>					

Changes in *Intangible assets, net* during the [thirty-nine](#) [thirteen](#) weeks ended [May 27, 2023](#) [November 25, 2023](#) were primarily related to recurring amortization expense. Amortization expense related to intangible assets was \$3.9 million and \$4.0 million for the thirteen weeks ended [May 27, 2023](#) [November 25, 2023](#) and [May 28, 2022](#), respectively, and \$11.8 million and \$11.9 million [\\$3.9 million](#) for the [thirty-nine](#) [thirteen](#) weeks ended [May 27, 2023](#) and [May 28, 2022](#), respectively, [November 26, 2022](#). There were no impairment charges related to intangible assets during the thirteen [and thirty-nine](#) weeks ended [May 27, 2023](#) [November 25, 2023](#) and [May 28, 2022](#) [November 26, 2022](#).

Estimated future amortization for each of the next five fiscal years and thereafter is as follows:

(In thousands)	(In thousands)	Amortization	(In thousands)	Amortization
Remainder of 2023		\$ 3,867		
2024		14,846		
Remainder of 2024			Remainder of 2024	\$ 11,721
2025	2025	13,554	2025	13,980
2026	2026	13,517	2026	13,740
2027	2027	13,517	2027	13,556
2028 and thereafter		78,350		
2028			2028	13,517
2029 and thereafter			2029 and thereafter	63,620
Total	Total	\$ 137,651	Total	\$ 130,134

5. Long-Term Debt and Line of Credit

On July 7, 2017, the Company (through certain of its subsidiaries) entered into the Credit Agreement. The Credit Agreement at that time provided for (i) a term facility of \$200.0 million ("Term Facility") with a seven-year maturity and (ii) a revolving credit facility of up to \$75.0 million (the "Revolving Credit Facility") with a five-year maturity. Substantially concurrent with the consummation of the business combination which formed the Company between Conyers Park Acquisition Corp. and NCP-ATK Holdings, Inc. on July 7, 2017, the full \$200.0 million of the Term Facility (the "Term Loan") was drawn.

On November 7, 2019, the Company entered into a second amendment (the "Incremental Facility Amendment") to the Credit Agreement to increase the principal borrowed on the Term Facility by \$460.0 million. The Term Facility together with the incremental borrowing make up the Initial Term Loans (as defined in the Incremental Facility Amendment). The Incremental Facility Amendment was executed to partially finance the acquisition of Quest Nutrition, LLC on November 7, 2019. No amounts under the Term Facility were repaid as a result of the execution of the Incremental Facility Amendment.

Effective as of December 16, 2021, the Company entered into a third amendment (the "Extension Amendment") to the Credit Agreement. The Extension Amendment provided for an extension of the stated maturity date of the Revolving Commitments and Revolving Loans (each as defined in the Credit Agreement) from July 7, 2022 to the earlier of (i) 91 days prior to the then-effective maturity date of the Initial Term Loans and (ii) December 16, 2026.

On January 21, 2022, the Company entered into the "2022 Repricing Amendment" to the Credit Agreement. The 2022 Repricing Amendment, among other things, (i) reduced the interest rate per annum applicable to the Initial Term Loans outstanding under the Credit Agreement immediately prior to the effective date of the 2022 Repricing Amendment, (ii) reset the prepayment premium for the existing Initial Term Loans to apply to Repricing Transactions (as defined in the Credit Agreement) that occur within six months after the effective date of the 2022 Repricing Amendment, and (iii) implemented SOFR and related replacement provisions for LIBOR.

On April 25, 2023, the Company entered into the "2023 Repricing Amendment" to the Credit Agreement. The 2023 Repricing Amendment, (i) reduced the interest rate per annum applicable to the Initial Term Loans outstanding under the Credit Agreement immediately prior to April 25, 2023, and (ii) provided for an extension of the maturity date of the Initial Term Loans from July 7, 2024, to March 17, 2027.

The 2023 Repricing Amendment did not change the interest rate on the Revolving Credit Facility, which continues to bear interest based upon the Company's consolidated net leverage ratio as of the end of the fiscal quarter for which consolidated financial statements are delivered to the Administrative Agent under the Credit Agreement. No additional debt was incurred, or any proceeds received by the Company in connection with the 2023 Repricing Amendment. No amounts under the Term Facility were repaid as a result of the execution of the 2023 Repricing Amendment.

Effective as of the 2023 Repricing Amendment, the interest rate per annum for the Initial Term Loans is based on either:

- A base rate equaling the higher of (a) the "prime rate," (b) the federal funds effective rate plus 0.50%, or (c) the Adjusted Term SOFR Rate (as defined in the Credit Agreement) applicable for an interest period of one month plus 1.00% plus (x) 1.50% margin for the Term Loan or (y) 2.00% margin for the Revolving Credit Facility; or
- SOFR plus a credit spread adjustment equal to 0.10% for one-month SOFR, 0.15% for up to three-month SOFR and 0.25% for up to six-month SOFR, subject to a floor of 0.50%, plus (x) 2.50% margin for the Term Loan or (y) 3.00% margin for the Revolving Credit Facility.

In connection with the closing of the 2023 Repricing Amendment, the Company expensed \$2.4 million primarily for third-party fees and capitalized an additional \$2.7 million primarily for the payment of upfront lender fees (original issue discount).

The Simply Good Foods Company is not a borrower under the Credit Agreement and has not provided a guarantee of the Credit Agreement. Simply Good Foods USA, Inc., is the administrative borrower and certain other subsidiary holding companies are co-borrowers under the Credit Agreement. Each of the Company's domestic subsidiaries that is not a named borrower under the Credit Agreement has provided a guarantee on a secured basis. As security for the payment or performance of the debt under the Credit Agreement, the borrowers and the guarantors have pledged certain equity interests in their respective subsidiaries and granted the lenders a security interest in substantially all of their domestic assets. All guarantors other than Quest Nutrition, LLC are holding companies with no assets other than their investments in their respective subsidiaries.

The Credit Agreement contains certain financial and other covenants that limit the Company's ability to, among other things, incur and/or undertake asset sales and other dispositions, liens, indebtedness, certain acquisitions and investments, consolidations, mergers, reorganizations and other fundamental changes, payment of dividends and other

distributions to equity and warrant holders, and prepayments of material subordinated debt, in each case, subject to customary exceptions materially consistent with credit facilities of such type and size. The Revolving Credit Facility has a maximum total net leverage ratio equal to or less than 6.00:1.00 contingent on credit extensions in excess of 30% of the total amount of commitments available under the Revolving Credit Facility. Any failure to comply with the restrictions of the credit facilities may result in an event of default. The Company was in compliance with all covenants as of **May 27, 2023** **November 25, 2023** and **August 27, 2022** **August 26, 2023**, respectively.

Long-term debt consists of the following:

(In thousands)	(In thousands)	May 27, 2023	August 27, 2022	(In thousands)	November 25, 2023	August 26, 2023
Term Facility (effective rate of 7.7% at May 27, 2023)		\$ 325,000	\$ 406,500			
Term Facility (effective rate of 8.0% at November 25, 2023)				Term Facility (effective rate of 8.0% at November 25, 2023)	\$ 275,000	\$ 285,000
Finance lease liabilities (effective rate of 5.6% at May 27, 2023)		202	406			
Finance lease liabilities (effective rate of 5.6% at November 25, 2023)				Finance lease liabilities (effective rate of 5.6% at November 25, 2023)	83	143
Less: Deferred financing fees	Less: Deferred financing fees	4,103	3,620	Less: Deferred financing fees	2,968	3,351
Total debt	Total debt	321,099	403,286	Total debt	272,115	281,792
Less: Current finance lease liabilities	Less: Current finance lease liabilities	199	264	Less: Current finance lease liabilities	83	143
Long-term debt, net of deferred financing fees	Long-term debt, net of deferred financing fees	\$ 320,900	\$ 403,022	Long-term debt, net of deferred financing fees	\$ 272,032	\$ 281,649

The Company is not required to make principal payments on the Term Facility over the twelve months following the period ended **May 27, 2023** **November 25, 2023**. The outstanding balance of the Term Facility is due upon its maturity in March 2027.

As of **May 27, 2023** **November 25, 2023**, the Company had letters of credit in the amount of \$3.5 million outstanding. These letters of credit offset against the \$75.0 million availability of the Revolving Credit Facility and exist to support three of the Company's leased buildings and insurance programs relating to workers' compensation. No amounts were drawn against these letters of credit at **May 27, 2023** **November 25, 2023**.

The Company utilizes market approaches to estimate the fair value of certain outstanding borrowings by discounting anticipated future cash flows derived from the contractual terms of the obligations and observable market interest and foreign exchange rates. The Company carries debt at historical cost and discloses fair value. As of **May 27, 2023** **November 25, 2023** and **August 27, 2022** **August 26, 2023**, the book value of the Company's debt approximated fair value. The estimated fair value of the Term Loan is valued based on observable inputs and classified as Level 2 in the fair value hierarchy.

6. Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measurements, a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies, is used:

Level 1 – Valuations based on quoted prices for identical assets and liabilities in active markets.

Level 2 – Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

Level 3 – Valuations based on unobservable inputs reflecting the Company's own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

Level 3 Measurements

During the thirty-nine weeks ended May 28, 2022, the Company had outstanding liability-classified Private Warrants that allowed holders to purchase 6,700,000 shares Components of the Company's common stock. Such Private Warrants were held by Conyers Park Sponsor, LLC ("Conyers Park"), a related party, balance sheet such as accounts receivable, cash and were exercised on a cashless basis on January 7, 2022 resulting in a net issuance of 4,830,761 shares of the Company's common stock. As a result, there were no outstanding liability-classified Private Warrants cash equivalents and others approximated fair value as of **May 27, 2023** and **August 27, 2022** **November 25, 2023**. Refer to Note 10, Stockholders' Equity, for additional details regarding the cashless exercise of the Private Warrants.

The Company utilized the Black-Scholes model to estimate the fair value of the Private Warrants at each reporting date. The application of the Black-Scholes model utilizes significant assumptions, including volatility. Significant judgment is required in determining the expected volatility, historically the key assumption, of the Private Warrants. In order to determine the most accurate measure of this volatility, the Company measured expected volatility based on several inputs, including considering a peer group of publicly traded companies, the Company's implied volatility based on traded options, the implied volatility of comparable warrants, and the implied volatility of any outstanding public warrants during the periods they were outstanding. As a result of the unobservable inputs that were used to determine the expected volatility of the Private Warrants, the fair value measurement of these warrants reflected a Level 3 measurement within the fair value measurement hierarchy.

The periodic remeasurement of the warrant liability has been reflected in Loss in fair value change of warrant liability within the Consolidated Statements of Operations and Comprehensive Income. The adjustment for the thirty-nine weeks ended May 28, 2022 was a gain of \$30.1 million.

7. Income Taxes

The tax expense and the effective tax rate resulting from operations were as follows:

(In thousands)	(In thousands)	Thirty-Nine Weeks Ended		(In thousands)	Thirteen Weeks Ended	
		May 27, 2023	May 28, 2022		November 25, 2023	November 26, 2022
Income before income taxes	Income before income taxes	\$ 126,743	\$ 113,173	Income before income taxes	\$ 47,108	\$ 45,556
Provision for income taxes	Provision for income taxes	\$ 29,810	\$ 34,726	Provision for income taxes	\$ 11,547	\$ 9,696
Effective tax rate	Effective tax rate	23.5 %	30.7 %	Effective tax rate	24.5 %	21.3 %

The effective tax rate for the ~~thirty-nine~~thirteen weeks ended ~~May 27, 2023~~ November 25, 2023 was ~~7.2% less~~3.2% more than the effective tax rate for the ~~thirty-nine~~thirteen weeks ended ~~May 28, 2022~~ November 26, 2022, which was primarily driven by the non-cash change in the fair value of the warrant liability in the prior fiscal period and other permanent differences.

8. Leases

The components of lease expense were as follows:

(In thousands)	(In thousands)	Statements of Operations Caption	Thirteen Weeks Ended		Thirty-Nine Weeks Ended		(In thousands)	Statements of Operations Caption	Thirteen Weeks Ended	
			May 27, 2023	May 28, 2022	May 27, 2023	May 28, 2022			November 25, 2023	November 26, 2022
Operating lease cost:	Operating lease cost:						Operating lease cost:			
		<i>Cost of goods sold and General and administrative</i>						<i>Cost of goods sold and General and administrative</i>		
Lease cost	Lease cost		\$ 2,245	\$ 2,278	\$ 6,745	\$ 6,806	Lease cost		\$ 2,259	\$ 2,252
		<i>Cost of goods sold and General and administrative</i>						<i>Cost of goods sold and General and administrative</i>		
Variable lease cost ⁽¹⁾	Variable lease cost ⁽¹⁾		1,047	787	2,565	2,300	Variable lease cost ⁽¹⁾		796	738
Total operating lease cost	Total operating lease cost		3,292	3,065	9,310	9,106	Total operating lease cost		3,055	2,990
Finance lease cost:	Finance lease cost:						Finance lease cost:			
Amortization of right-of-use assets	Amortization of right-of-use assets	<i>Cost of goods sold</i>	58	69	189	205	Amortization of right-of-use assets	<i>Cost of goods sold</i>	53	68
Interest on lease liabilities	Interest on lease liabilities	<i>Interest expense</i>	3	7	12	24	Interest on lease liabilities	<i>Interest expense</i>	1	5
Total finance lease cost	Total finance lease cost		61	76	201	229	Total finance lease cost		54	73
Total lease cost	Total lease cost		\$ 3,353	\$ 3,141	\$ 9,511	\$ 9,335	Total lease cost		\$ 3,109	\$ 3,063

⁽¹⁾ Variable lease cost primarily consists of common area maintenance, such as cleaning and repairs.

The right-of-use assets and corresponding liabilities related to both operating and finance leases are as follows:

(In thousands)	(In thousands)	Balance Sheets Caption	May 27, 2023	August 27, 2022	(In thousands)	Balance Sheets Caption	November 25, 2023	August 26, 2023
Assets	Assets				Assets			
Operating lease right-of-use assets	Operating lease right-of-use assets	<i>Other long-term assets</i>	\$ 41,444	\$ 46,460	Operating lease right-of-use assets	<i>Other long-term assets</i>	\$ 38,286	\$ 40,022
Finance lease right-of-use assets	Finance lease right-of-use assets	<i>Property and equipment, net</i>	178	367	Finance lease right-of-use assets	<i>Property and equipment, net</i>	73	125
Total lease assets	Total lease assets		\$ 41,622	\$ 46,827	Total lease assets		\$ 38,359	\$ 40,147

Liabilities	Liabilities				Liabilities	Liabilities			
Current:	Current:				Current:	Current:			
Operating lease liabilities	Operating lease liabilities	Accrued expenses and other current liabilities	\$ 7,396	\$ 6,249	Operating lease liabilities	Accrued expenses and other current liabilities	\$ 7,724	\$ 7,566	
		Current maturities of long-term				Current maturities of long-term			
Finance lease liabilities	Finance lease liabilities	debt	199	264	Finance lease liabilities	debt	83	143	
Long-term:	Long-term:				Long-term:	Long-term:			
Operating lease liabilities	Operating lease liabilities	Other long-term liabilities	38,933	44,482	Operating lease liabilities	Other long-term liabilities	35,306	37,272	
		Long-term debt, less current				Long-term debt, less current			
Finance lease liabilities	Finance lease liabilities	maturities	3	142	Finance lease liabilities	maturities	—	—	
Total lease liabilities	Total lease liabilities		\$ 46,531	\$ 51,137	Total lease liabilities			\$ 43,113	\$ 44,981

Future maturities of lease liabilities as of **May 27, 2023** **November 25, 2023** were as follows:

(In thousands)	(In thousands)	Operating Leases	Finance Leases	(In thousands)	Operating Leases	Finance Leases
Fiscal year ending:	Fiscal year ending:			Fiscal year ending:		
Remainder of 2023		2,321	61			
2024		9,424	145			
Remainder of 2024				Remainder of 2024	7,145	84
2025	2025	8,680	—	2025	8,750	—
2026	2026	6,880	—	2026	6,952	—
2027	2027	7,036	—	2027	7,110	—
2028				2028	6,447	—
Thereafter	Thereafter	19,848	—	Thereafter	13,496	—
Total lease payments	Total lease payments	54,189	206	Total lease payments	49,900	84
Less: Interest	Less: Interest	(7,860)	(4)	Less: Interest	(6,870)	(1)
Present value of lease liabilities	Present value of lease liabilities	\$ 46,329	\$ 202	Present value of lease liabilities	\$ 43,030	\$ 83

The weighted-average remaining lease terms and weighted-average discount rates for operating and finance leases were as follows:

		May 27, 2023	August 27, 2022		November 25, 2023	August 26, 2023
Weighted-average remaining lease term (in years)	Weighted-average remaining lease term (in years)			Weighted-average remaining lease term (in years)		
Operating leases	Operating leases	6.69	7.27	Operating leases	6.08	6.24
Finance leases	Finance leases	0.85	1.51	Finance leases	0.37	0.61
Weighted-average discount rate	Weighted-average discount rate			Weighted-average discount rate		
Operating leases	Operating leases	4.7 %	4.7 %	Operating leases	4.4 %	4.4 %
Finance leases	Finance leases	5.6 %	5.6 %	Finance leases	5.6 %	5.6 %

Supplemental and other information related to leases was as follows:

		Thirty-Nine Weeks Ended			Thirteen Weeks Ended	
(In thousands)	(In thousands)	May 27, 2023	May 28, 2022	(In thousands)	November 25, 2023	November 26, 2022
Cash paid for amounts included in the measurement of lease liabilities	Cash paid for amounts included in the measurement of lease liabilities			Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flows from operating leases	Operating cash flows from operating leases	\$ 7,905	\$ 7,155	Operating cash flows from operating leases	\$ 2,926	\$ 2,040

Operating cash flows from finance leases	Operating cash flows from finance leases	\$	394	\$	472	Operating cash flows from finance leases	\$	175	\$	131
Financing cash flows from finance leases	Financing cash flows from finance leases	\$	217	\$	235	Financing cash flows from finance leases	\$	61	\$	78

9. Commitments and Contingencies

Litigation

The Company is a party to certain litigation and claims that are considered normal to the operations of the business. From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of business. The Company is not presently a party to any litigation that it believes to be material, and the Company is not aware of any pending or threatened litigation against it that its management believes could have a material adverse effect on its business, operating results, financial condition or cash flows.

Other

The Company has entered into endorsement contracts with certain celebrity figures and social media influencers to promote and endorse the Atkins Quest® and Quest Atkins® brands and product lines. These contracts contain endorsement fees, which are expensed ratably over the life of the contract, and performance fees, that are recognized at the time of achievement. Based on the terms of the contracts in place and achievement of performance conditions as of May 27, 2023 November 25, 2023, the Company will be required to make payments of \$3.3 million \$2.9 million over the next year.

10. Stockholders' Equity

Stock Repurchase Program

The Company adopted a \$50.0 million stock repurchase program on November 13, 2018. On April 13, 2022, and October 21, 2022, the Company announced that its Board of Directors had approved the addition of \$50.0 million and \$50.0 million, respectively, to its stock repurchase program, resulting in authorized stock repurchases of up to an aggregate of \$150.0 million. Under the stock repurchase program, the Company may repurchase shares from time to time in the open market or in privately negotiated transactions. The stock repurchase program does not obligate the Company to acquire any specific number of shares or acquire shares over any specific period of time. The stock repurchase program may be suspended or discontinued at any time by the Company and does not have an expiration date.

The Company did not repurchase any shares of common stock during the thirteen weeks ended May 27, 2023 November 25, 2023. During the thirty-nine thirteen weeks ended May 27, 2023 November 26, 2022, the Company repurchased 546,346 shares of common stock at an average share price of \$30.11 per share. During the thirteen weeks ended May 28, 2022, the Company repurchased 218,221 shares of common stock at an average share price of 37.16 per share. During the thirty-nine weeks ended May 28, 2022, the Company repurchased 789,742 shares of common stock at an average share price of \$36.09. As of May 27, 2023 November 25, 2023, approximately \$71.5 million remained available under the stock repurchase program.

Warrants to Purchase Common Stock

During the thirteen and thirty-nine weeks ended May 28, 2022, the Company had outstanding liability-classified Private Warrants that allowed holders to purchase 6,700,000 shares of the Company's common stock. Such Private Warrants were held by Conyers Park, a related party. Each whole warrant entitled the holder to purchase one share of the Company's common stock at a price of \$11.50 per share. On January 7, 2022, Conyers Park elected to exercise the Private Warrants on a cashless basis, resulting in a net issuance of 4,830,761 shares of the Company's common stock. As a result of the cashless exercise on January 7, 2022, there were no outstanding liability-classified Private Warrants as of May 27, 2023 and August 27, 2022.

As discussed in Note 6, Fair Value of Financial Instruments, the liability-classified warrants were remeasured on a recurring basis, primarily based on observable market data while the related theoretical private warrant volatility assumption within the Black-Scholes model represents a Level 3 measurement within the fair value measurement hierarchy. The periodic fair value remeasurements of the warrant liability have been reflected in Loss in fair value change of warrant liability within the Consolidated Statements of Operations and Comprehensive Income.

11. Earnings Per Share

Basic earnings or loss per share is based on the weighted average number of common shares issued and outstanding. In computing diluted earnings per share, basic earnings per share is adjusted for the assumed issuance of all potentially dilutive securities, including the Company's employee stock options and non-vested stock units, and Private Warrants for the periods during which they were outstanding. During periods when the effect of the outstanding Private Warrants was dilutive, the Company assumed share settlement of the instruments as of the beginning of the reporting period and adjusted the numerator to remove the change in fair value of the warrant liability and adjusted the denominator to include the dilutive shares, calculated using the treasury stock method. During periods when the effect of the outstanding Private Warrants was anti-dilutive, the share settlement was excluded. units.

In periods in which the Company has a net loss, diluted loss per share is based on the weighted average number of common shares issued and outstanding as the effect of including common stock equivalents outstanding would be anti-dilutive.

The following table reconciles the numerators and denominators used in the computations of both basic and diluted earnings per share:

	Thirteen Weeks Ended	Thirty-Nine Weeks Ended	Thirteen Weeks Ended
--	----------------------	-------------------------	----------------------

(In thousands, except per share data)	(In thousands, except per share data)	May 27, 2023	May 28, 2022	May 27, 2023	May 28, 2022	(In thousands, except per share data)	November 25, 2023	November 26, 2022
Basic earnings per share computation:	Basic earnings per share computation:					Basic earnings per share computation:		
Numerator:	Numerator:					Numerator:		
Net income available to common stockholders	Net income available to common stockholders	\$ 35,431	\$ 38,834	\$ 96,933	\$ 78,447	Net income available to common stockholders	\$ 35,561	\$ 35,860
Denominator:	Denominator:					Denominator:		
Weighted average common shares outstanding - basic	Weighted average common shares outstanding - basic	99,518,546	100,426,227	99,404,174	98,294,114	Weighted average common shares outstanding - basic	99,629,188	99,200,557
Basic earnings per share from net income	Basic earnings per share from net income	\$ 0.36	\$ 0.39	\$ 0.98	\$ 0.80	Basic earnings per share from net income	\$ 0.36	\$ 0.36
Diluted earnings per share computation:	Diluted earnings per share computation:					Diluted earnings per share computation:		
Numerator:	Numerator:					Numerator:		
Net income available for common stockholders	Net income available for common stockholders	\$ 35,431	\$ 38,834	\$ 96,933	\$ 78,447	Net income available for common stockholders	\$ 35,561	\$ 35,860
Numerator for diluted earnings per share	Numerator for diluted earnings per share	\$ 35,431	\$ 38,834	\$ 96,933	\$ 78,447	Numerator for diluted earnings per share	\$ 35,561	\$ 35,860
Denominator:	Denominator:					Denominator:		
Weighted average common shares outstanding - basic	Weighted average common shares outstanding - basic	99,518,546	100,426,227	99,404,174	98,294,114	Weighted average common shares outstanding - basic	99,629,188	99,200,557
Employee stock options	Employee stock options	1,228,922	1,604,847	1,256,898	1,633,278	Employee stock options	1,172,483	1,299,543
Non-vested stock units	Non-vested stock units	162,504	206,383	186,898	262,676	Non-vested stock units	293,065	222,936
Weighted average common shares - diluted	Weighted average common shares - diluted	100,909,972	102,237,457	100,847,970	100,190,068	Weighted average common shares - diluted	101,094,736	100,723,036
Diluted earnings per share from net income	Diluted earnings per share from net income	\$ 0.35	\$ 0.38	\$ 0.96	\$ 0.78	Diluted earnings per share from net income	\$ 0.35	\$ 0.36

Diluted earnings per share calculations for the thirteen and thirty-nine weeks ended May 27, 2023 November 25, 2023 and November 26, 2022 excluded 0.7 0.8 million and 0.6 million shares of common stock issuable upon exercise of stock options, respectively, that would have been anti-dilutive. Diluted earnings per share calculations for the thirteen and thirty-nine weeks ended May 28, 2022 excluded 0.3 million and 0.3 0.4 million shares of common stock issuable upon exercise of stock options, respectively, that would have been anti-dilutive.

Diluted earnings per share calculations for the thirteen and thirty-nine weeks ended May 27, 2023 November 25, 2023 and November 26, 2022 excluded an immaterial amount number of shares and 0.1 million shares of non-vested stock units, that would have been anti-dilutive. Diluted earnings per share calculations for the thirteen and thirty-nine weeks ended May 28, 2022 excluded an immaterial amount of non-vested stock units that would have been anti-dilutive.

The diluted earnings per share calculations for the thirty-nine weeks ended May 28, 2022 excluded 1.0 million shares issuable upon exercise of Private Warrants respectively, that would have been anti-dilutive.

12. Omnibus Incentive Plan

Stock-based compensation includes stock options, restricted stock units, performance stock unit awards and stock appreciation rights, which are awarded to employees, directors, and consultants of the Company. Stock-based compensation expense for equity-classified awards is recognized on a straight-line basis over the requisite service period of the award based on their grant date fair value. Stock-based compensation expense is included within *General and administrative* expense, which is the same financial statement caption where the recipient's other compensation is reported.

The Company recorded stock-based compensation expense of \$4.1 \$4.2 million and \$3.0 \$3.3 million in the thirteen weeks ended May 27, 2023 November 25, 2023 and May 28, 2022, respectively, and \$10.5 million and \$8.7 million in the thirty-nine weeks ended May 27, 2023 and May 28, 2022 November 26, 2022, respectively.

Stock Options

The following table summarizes stock option activity for the thirty-nine thirteen weeks ended May 27, 2023 November 25, 2023:

Shares underlying options	Weighted average exercise price	Weighted average remaining contractual life (years)
---------------------------	---------------------------------	---

Outstanding as of August 27, 2022	2,776,551	\$	18.04	6.10
Granted	285,001		37.73	
Exercised	(346,956)		14.51	
Forfeited	(35,624)		32.04	
Outstanding as of May 27, 2023	2,678,972	\$	20.41	5.86
Vested and expected to vest as of May 27, 2023	2,678,972	\$	20.41	5.86
Exercisable as of May 27, 2023	2,029,757	\$	15.60	4.93

	Shares underlying options	Weighted average exercise price	Weighted average remaining contractual life (years)
Outstanding as of August 26, 2023	2,668,462	\$ 20.41	5.56
Granted	17,633	33.02	
Exercised	—	—	
Forfeited	(3,815)	39.38	
Outstanding as of November 25, 2023	2,682,280	\$ 20.47	5.35
Vested and expected to vest as of November 25, 2023	2,682,280	\$ 20.47	5.35
Exercisable as of November 25, 2023	2,188,820	\$ 16.69	4.64

As of May 27, 2023 November 25, 2023, the Company had \$6.4 million \$4.8 million of total unrecognized compensation cost related to stock options that will be recognized over a weighted average period of 1.8 1.5 years. During the thirty-nine thirteen weeks ended May 27, 2023 and May 28, 2022 November 25, 2023 the Company did not receive cash from stock option exercises. During the thirteen weeks ended November 26, 2022, the Company received \$5.0 million and \$4.3 million \$4.6 million in cash from stock option exercises, respectively.

Restricted Stock Units

The following table summarizes restricted stock unit activity for the thirty-nine thirteen weeks ended May 27, 2023 November 25, 2023:

	Units	Weighted average grant-date fair value		Units	Weighted average grant-date fair value
Non-vested as of August 27, 2022	453,003	\$ 30.68			
Non-vested as of August 26, 2023			Non-vested as of August 26, 2023	514,498	\$ 35.59
Granted	289,046	37.16	Granted	194,353	36.94
Vested	(203,880)	28.11	Vested	(151,239)	30.34
Forfeited	(48,883)	33.38	Forfeited	(7,589)	38.69
Non-vested as of May 27, 2023	489,286	\$ 35.31			
Non-vested as of November 25, 2023			Non-vested as of November 25, 2023	550,023	\$ 37.47

As of May 27, 2023 November 25, 2023, the Company had \$11.9 million \$15.6 million of total unrecognized compensation cost related to restricted stock units that will be recognized over a weighted average period of 1.5 1.8 years.

Performance Stock Units

During the thirty-nine thirteen weeks ended May 27, 2023 November 25, 2023, the Company granted performance stock units under its equity compensation plan. Performance stock units vest in a range between 0% and 200% based upon certain performance criteria in a three-year period. Performance stock units were valued using a Monte Carlo simulation.

The following table summarizes performance stock unit activity for the thirty-nine thirteen weeks ended May 27, 2023 November 25, 2023:

	Units	Weighted average grant-date fair value		Units	Weighted average grant-date fair value
Non-vested as of August 27, 2022	255,023	\$ 32.82			
Non-vested as of August 26, 2023			Non-vested as of August 26, 2023	191,779	\$ 42.41
Granted	50,629	62.55	Granted	178,788	38.66
Vested	(72,452)	27.39	Vested	(189,884)	21.52

Forfeited	Forfeited	(37,241)	31.00	Forfeited	—	—
Non-vested as of May 27, 2023		195,959	\$ 42.85			
Non-vested as of November 25, 2023				Non-vested as of November 25, 2023	180,683	\$ 59.28

As of May 27, 2023 November 25, 2023, the Company had \$4.2 million \$7.6 million of total unrecognized compensation cost related to performance stock units that will be recognized over a weighted average period of 1.22.2 years.

Stock Appreciation Rights

Stock appreciation rights ("SARs") permit the holder to participate in the appreciation of the Company's common stock price and are awarded to non-employee consultants of the Company. The Company's SARs settle in shares of its common stock once the applicable vesting criteria have been met. The SARs outstanding as of May 27, 2023 November 25, 2023 cliff vest two years from the date of grant and must be exercised within five years.

The following table summarizes SARs activity for the thirty-nine thirteen weeks ended May 27, 2023 November 25, 2023:

		Shares underlying SARs	Weighted average exercise price		Shares underlying SARs	Weighted average exercise price
Outstanding as of August 27, 2022		150,000	\$ 24.20			
Outstanding as of August 26, 2023				Outstanding as of August 26, 2023	150,000	\$ 37.67
Granted	Granted	150,000	37.67	Granted	—	—
Exercised	Exercised	(150,000)	24.20	Exercised	—	—
Forfeited	Forfeited	—	—	Forfeited	—	—
Outstanding as of May 27, 2023		150,000	\$ 37.67			
Outstanding as of November 25, 2023				Outstanding as of November 25, 2023	150,000	\$ 37.67

The SARs exercised in the thirty-nine thirteen weeks ended May 27, 2023 November 26, 2022 resulted in a net issuance of 38,850 shares of the Company's common stock. The SARs granted in the thirty-nine thirteen weeks ended May 27, 2023 November 26, 2022 are liability-classified; therefore the related stock-based compensation expense is based on the vesting provisions and the fair value of the awards.

13. Restructuring and Related Charges

In May 2020, the Company announced certain restructuring activities in conjunction with the implementation of the Company's future-state organization design, which created a fully integrated organization with its completed acquisition of Quest Nutrition, LLC on November 7, 2019. The new organization design became effective on August 31, 2020. These restructuring plans primarily included workforce reductions, changes in management structure, and the relocation of business activities from one location to another.

The Company substantially completed its restructuring activities during the third quarter of fiscal 2022; therefore no restructuring or restructuring-related costs were incurred in the thirteen and thirty-nine weeks ended May 27, 2023 and the thirteen weeks ended May 28, 2022. During the thirty-nine weeks ended May 28, 2022, the Company incurred \$0.1 million of restructuring and restructuring-related costs. Since the announcement of the restructuring activities in May 2020, the Company incurred aggregate restructuring and restructuring-related costs of \$9.9 million.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q (this "Report") contains forward-looking statements. When used anywhere in this Report, the words "expect," "believe," "anticipate," "estimate," "intend," "plan" and similar expressions are intended to identify forward-looking statements. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. These statements include, but are not limited to, our expectations regarding our supply chain, including but not limited to, raw materials and logistics costs, the effect of price increases, inflationary pressure on us and our contract manufacturers, and the unforeseen business disruptions or other effects due to current global geopolitical tensions, including relating to Ukraine. tension. We disclaim any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, except as required by applicable law. These statements reflect our current views with respect to future events and are based on assumptions subject to risks and uncertainties. Such risks and uncertainties include those related to our ability to sell our products.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended August 27, 2022 August 26, 2023 ("Annual Report") and our unaudited consolidated financial statements and the related notes appearing elsewhere in this Report. In addition to historical information, the following discussion contains forward-looking statements, including, but not limited to, statements regarding the Company's expectation for future performance, liquidity and capital resources that involve risks, uncertainties and assumptions that could cause actual

results to differ materially from the Company's expectations. The Company's actual results may differ materially from those contained in or implied by any forward-looking statements. Factors that could cause such differences include those identified in Item 1A. "Risk Factors" of our Annual Report. The Company assumes no obligation to update any of these forward-looking statements.

Unless the context requires otherwise in this Report, the terms "we," "us," "our," the "Company" and "Simply Good Foods" refer to The Simply Good Foods Company and its subsidiaries.

Overview

The Simply Good Foods Company is a consumer packaged food and beverage company that aims to lead the nutritious snacking movement with trusted brands that offer a variety of convenient, innovative, great-tasting, better-for-you snacks and meal replacements, and other product offerings. The product portfolio we develop, market and sell consists primarily of protein bars, ready-to-drink ("RTD") shakes, sweet and salty snacks and confectionery products marketed under the Atkins®, Atkins Endulge®, Quest® and Quest Hero™ Atkins® brand names. We believe Simply Good Foods is poised to expand its wellness platform through innovation and organic growth along with acquisition opportunities in the nutritional snacking space.

Our nutritious snacking platform consists of brands that specialize in providing products for consumers that follow certain nutritional philosophies and health-and-wellness trends: Atkins® for those following a low-carb lifestyle and Quest® for consumers seeking a variety of protein-rich foods and beverages that also limit sugars and simple carbs, carbs and Atkins® for those following a low-carb lifestyle. We distribute our products in major retail channels, primarily in North America, including grocery, club, and mass merchandise, as well as through e-commerce, convenience, specialty, and other channels. Our portfolio of nutritious snacking brands gives us a strong platform with which to introduce new products, expand distribution, and attract new consumers to our products.

Business Trends

We continue to actively monitor During fiscal 2023 the effect of the dynamic macroeconomic inflationary environment in the United States and elsewhere, elevated levels of supply chain costs, and the level of consumer mobility, which includes the rate at which consumers return to working outside the home. Current or future governmental policies may increase the risk of inflation and possible economic recession, which could further increase the costs of ingredients, packaging and finished goods for our business as well as negatively effect consumer behavior and demand for our products. Additionally, management is continuing to monitor the conflict in Ukraine, especially regarding the availability and cost of raw materials that are produced in this region and Europe in general. Management is also monitoring for signs of any expansion of economic or supply chain disruptions or broader supply chain inflationary costs resulting either directly or indirectly from the crisis in Eastern Europe.

During the thirteen and thirty-nine weeks ended May 27, 2023, our business performance Company was affected by the corresponding unfavorable effects of higher raw material costs, higher co-manufacturing costs, and supply chain challenges, including supply chain disruptions resulting from labor shortages and disruptions in ingredients, and we expect on balance that these inflationary cost pressures and supply chain challenges to continue for the remainder of fiscal year 2023. ingredients.

We continue During the thirteen weeks ended November 25, 2023, our business performance improved as strong Quest sales volume growth more than offset Atkins softness. The Company benefited from lower ingredient and packaging costs which resulted in gross margin expansion versus the year ago period. The Company continues to proactively engage and have discussions with our retail customers, its contract manufacturers and logistics and transportation providers to meet have its cost structure reflect lower market prices. We believe the Company's strategy and positioning will continue to drive profitable growth for our product offerings and growth within the growing nutritional snacking category.

We continue to actively monitor the dynamic supply chain environment in the United States and elsewhere as well as consumer purchasing behavior. Current or future governmental policies may increase the risk of inflation and possible economic recession, which could increase the costs of ingredients, packaging, logistics and finished goods for our business as well as negatively effect consumer behavior and demand for our products and to remain informed of any challenges within our business operations. Additionally, we instituted price increases effective in the first and fourth quarters of fiscal year 2022. Management believes these price increases and additional cost savings initiatives will partially offset the unfavorable effects of the supply chain cost pressures discussed above. products.

Based on information available to us as of the date of this Report, we believe we will be able to deliver products at acceptable levels to fulfill customer orders on a timely basis; therefore, we expect our products will continue to be available for purchase to meet consumer meal replacement and snacking needs for the foreseeable future. We continue to monitor customer and consumer demand along with our supply chain and logistics capabilities and intend to adapt our plans as needed to continue to drive our business and meet our obligations.

Key Financial Definitions

Net sales. Net sales consist primarily of product sales less the cost of promotional activities, slotting fees and other sales credits and adjustments, including product returns.

Cost of goods sold. Cost of goods sold consists primarily of the costs we pay to our contract manufacturing partners to produce the products sold. These costs include the purchase of raw ingredients, packaging, shipping and handling, warehousing, depreciation of warehouse equipment, and a tolling charge for the contract manufacturer. Cost of goods sold includes products provided at no charge as part of promotions and the non-food materials provided with customer orders.

Operating expenses. Operating expenses consist primarily of selling and marketing, general and administrative, and depreciation and amortization expense. The following is a brief description of the components of operating expenses:

- *Selling and marketing.* Selling and marketing expenses comprise broker commissions, customer marketing, media and other marketing costs.
- *General and administrative.* General and administrative expenses comprise expenses associated with corporate and administrative functions that support our business, including employee compensation, stock-based compensation, professional services, **executive transition costs**, integration costs, restructuring costs, insurance and other general corporate expenses.
- *Depreciation and amortization.* Depreciation and amortization costs consist of costs associated with the depreciation of fixed assets and capitalized leasehold improvements and amortization of intangible assets.

Results of Operations

During the thirteen weeks ended **May 27, 2023** **November 25, 2023**, our net sales increased slightly to **\$324.8 million** **\$308.7 million** compared to **\$316.5** **\$300.9 million** for the thirteen weeks ended **May 28, 2022**. The positive effects of the price increase effective **November 26, 2022**, driven by Quest volume growth, which offset softness in the fourth quarter of fiscal year 2022 drove Atkins net sales, resulting in a 2.6% increase in our aggregate North America net sales. Unfavorable effects of higher raw material, packaging, and co-manufacturing costs and supply chain challenges in the thirteen weeks ended **May 27, 2023** resulted in decreased gross **Gross** profit and gross profit margin as compared to the thirteen weeks ended **May 28, 2022**. As previously discussed above in "Business Trends," we expect these inflationary cost pressures improved driven by higher sales volumes and supply chain challenges to continue for the remainder of fiscal year 2023. **lower ingredient and packaging costs.**

In assessing the performance of our business, we consider a number of key performance indicators used by management and typically used by our competitors, including the non-GAAP measures EBITDA and Adjusted EBITDA. Because not all companies use identical calculations, this presentation of EBITDA and Adjusted EBITDA may not be comparable to other similarly titled measures of other companies. See "Reconciliation of EBITDA and Adjusted EBITDA" below for a reconciliation of EBITDA and Adjusted EBITDA to net income for each applicable period.

Comparison of Unaudited Results for the Thirteen Weeks Ended **May 27, 2023** **November 25, 2023** and the Thirteen Weeks Ended **May 28, 2022** **November 26, 2022**

The following unaudited table presents, for the periods indicated, selected information from our Consolidated Statements of Operations and Comprehensive Income, including information presented as a percentage of net sales:

		Thirteen Weeks Ended		Thirteen Weeks Ended			Thirteen Weeks Ended		Thirteen Weeks Ended	
			% of Net		% of Net		November 25,	% of Net	November 26,	% of Net
(In thousands)	(In thousands)	May 27, 2023	Sales	May 28, 2022	Sales	(In thousands)	2023	Sales	2022	Sales
Net sales	Net sales	\$ 324,792	100.0 %	\$ 316,531	100.0 %	Net sales	\$ 308,678	100.0 %	\$ 300,878	100.0 %
Cost of goods sold	Cost of goods sold	205,546	63.3 %	197,883	62.5 %	Cost of goods sold	193,560	62.7 %	189,886	63.1 %
Gross profit	Gross profit	119,246	36.7 %	118,648	37.5 %	Gross profit	115,118	37.3 %	110,992	36.9 %
Operating expenses:	Operating expenses:					Operating expenses:				
Selling and marketing	Selling and marketing	30,168	9.3 %	32,334	10.2 %	Selling and marketing	31,990	10.4 %	28,534	9.5 %
General and administrative	General and administrative	30,510	9.4 %	26,721	8.4 %	General and administrative	26,950	8.7 %	25,641	8.5 %
Depreciation and amortization	Depreciation and amortization	4,363	1.3 %	4,317	1.4 %	Depreciation and amortization	4,358	1.4 %	4,327	1.4 %
Total operating expenses	Total operating expenses	65,041	20.0 %	63,372	20.0 %	Total operating expenses	63,298	20.5 %	58,502	19.4 %
Income from operations	Income from operations	54,205	16.7 %	55,276	17.5 %	Income from operations	51,820	16.8 %	52,490	17.4 %
Other income (expense):	Other income (expense):					Other income (expense):				
Interest income	Interest income	407	0.1 %	—	— %	Interest income	1,090	0.4 %	7	— %
Interest expense	Interest expense	(7,649)	(2.4) %	(4,881)	(1.5) %	Interest expense	(6,034)	(2.0) %	(7,055)	(2.3) %
Gain on foreign currency transactions	Gain on foreign currency transactions	180	0.1 %	76	— %	Gain on foreign currency transactions	226	0.1 %	108	— %
Other income	Other income	4	— %	17	— %	Other income	6	— %	6	— %
Total other expense	Total other expense	(7,058)	(2.2) %	(4,788)	(1.5) %	Total other expense	(4,712)	(1.5) %	(6,934)	(2.3) %
Income before income taxes	Income before income taxes	47,147	14.5 %	50,488	16.0 %	Income before income taxes	47,108	15.3 %	45,556	15.1 %
Income tax expense	Income tax expense	11,716	3.6 %	11,654	3.7 %	Income tax expense	11,547	3.7 %	9,696	3.2 %
Net income	Net income	\$ 35,431	10.9 %	\$ 38,834	12.3 %	Net income	\$ 35,561	11.5 %	\$ 35,860	11.9 %
Other financial data:	Other financial data:					Other financial data:				
Adjusted EBITDA ⁽¹⁾	Adjusted EBITDA ⁽¹⁾	\$ 66,635	20.5 %	\$ 63,291	20.0 %	Adjusted EBITDA ⁽¹⁾	\$ 61,965	20.1 %	\$ 60,766	20.2 %

(1) Adjusted EBITDA is a non-GAAP financial metric. See "Reconciliation of EBITDA and Adjusted EBITDA" below for a reconciliation of net income to EBITDA and Adjusted EBITDA for each applicable period.

Net sales. Net sales were \$324.8 million \$308.7 million for the thirteen weeks ended May 27, 2023 November 25, 2023 compared to \$316.5 \$300.9 million for the thirteen weeks ended May 28, 2022 November 26, 2022, representing an increase of \$8.3 million. Price increases effective in the fourth quarter of fiscal year 2022 contributed to the 2.6% increase in our \$7.8 million, driven primarily by Quest volume growth which offset Atkins softness. North America net sales increased 2.6% in the thirteen weeks ended May 27, 2023 November 25, 2023 compared to the thirteen weeks ended May 28, 2022 November 26, 2022, and International net sales increased 0.7% during the same period.

Cost of goods sold. Cost of goods sold increased \$7.7 million \$3.7 million, or 3.9% 1.9%, for the thirteen weeks ended May 27, 2023 November 25, 2023 compared to the thirteen weeks ended May 28, 2022 November 26, 2022. The cost of goods sold increase was primarily driven by higher raw material, packaging, and co-manufacturing costs and supply chain challenges sales volumes in the thirteen weeks ended May 27, 2023 November 25, 2023.

Gross profit. Gross profit increased by \$0.6 million \$4.1 million, or 0.5% 3.7%, for the thirteen weeks ended May 27, 2023 November 25, 2023 compared to the thirteen weeks ended May 28, 2022 November 26, 2022. Additionally, gross profit of \$119.2 million \$115.1 million, or 36.7% 37.3% of net sales, for the thirteen weeks ended May 27, 2023 decreased 80 November 25, 2023 increased 40 basis points from 37.5% 36.9% of net sales for the thirteen weeks ended May 28, 2022 November 26, 2022. The decrease increase in gross profit margin was primarily driven by the unfavorable effects of higher raw material, lower ingredient and packaging and co-manufacturing costs and supply chain challenges in the thirteen weeks ended May 27, 2023 as previously discussed. This decrease was partially offset by the favorable effects of the price increase which became effective in the fourth quarter of fiscal year 2022. costs.

Operating expenses. Operating expenses increased \$1.7 million \$4.8 million, or 2.6% 8.2%, for the thirteen weeks ended May 27, 2023 November 25, 2023 compared to the thirteen weeks ended May 28, 2022 November 26, 2022 due to the following:

- **Selling and marketing.** Selling and marketing expenses decreased \$2.2 million increased \$3.5 million, or 6.7% 12.1%, for the thirteen weeks ended May 27, 2023 November 25, 2023 compared to the thirteen weeks ended May 28, 2022 November 26, 2022, primarily due to expenses related to the timing of marketing spend, growth initiatives.
- **General and administrative.** General and administrative expenses increased \$3.8 million \$1.3 million, or 14.2% 5.1%, for the thirteen weeks ended May 27, 2023 November 25, 2023 compared to the thirteen weeks ended May 28, 2022 November 26, 2022. The increase in general and administrative expenses was primarily attributable to \$2.4 million of fees related to the extension of the Term Loan, \$0.9 million \$0.7 million of stock based compensation \$0.7 million expense, \$0.4 million of executive officer transition costs, and increased plant trial spend, partially offset by a reduction other investments in employee-related expenses and the discontinuation of costs related to business integration activities, organizational capabilities.
- **Depreciation and amortization.** Depreciation and amortization expenses were was \$4.4 million for the thirteen weeks ended May 27, 2023 November 25, 2023 and May 28, 2022, \$4.3 million for the thirteen weeks ended November 26, 2022, respectively.

Interest income. Interest income increased by \$1.0 million for the thirteen weeks ended November 25, 2023 compared to the thirteen weeks ended November 26, 2022, due to higher cash balances, the increase in interest rates, and other sources of interest income.

Interest expense. Interest expense increased \$2.8 million decreased \$1.0 million for the thirteen weeks ended May 27, 2023 November 25, 2023 compared to the thirteen weeks ended May 28, 2022 November 26, 2022, primarily due to the increase in interest rates on our Term Facility (as defined below) to 7.7% as of May 27, 2023 from 4.7% as of May 28, 2022. The increase was partially offset by the effect of principal payments reducing the outstanding balance of the Term Facility (as defined below) to \$325.0 million \$275.0 million as of May 27, 2023 November 25, 2023, from \$406.5 million \$400.0 million as of May 28, 2022 November 26, 2022. The reduction in the outstanding balance of the Term Facility was partially offset by the increase in interest rates on our Term Facility to 8.0% as of November 25, 2023 from 7.7% as of November 26, 2022. Additionally, interest expense related to the amortization of deferred financing costs and debt discount increased decreased \$0.1 million for the thirteen weeks ended May 27, 2023 November 25, 2023 compared to the thirteen weeks ended May 28, 2022 November 26, 2022.

Gain on foreign currency transactions. Foreign currency transactions resulted in a gain of \$0.2 million and a gain of \$0.1 million for the thirteen weeks ended May 27, 2023 November 25, 2023 and May 28, 2022 November 26, 2022, respectively. The variance is attributable to changes in foreign currency rates related to our international operations.

Income tax expense. Income tax expense increased \$0.1 million \$1.9 million for the thirteen weeks ended May 27, 2023 November 25, 2023 compared to the thirteen weeks ended May 28, 2022 November 26, 2022. The decrease increase in our income tax expense was primarily driven by lower higher income from operations and changes in permanent differences.

Net income. Net income was \$35.4 million \$35.6 million for the thirteen weeks ended May 27, 2023 November 25, 2023, a decrease of \$3.4 million \$0.3 million compared to net income of \$38.8 million \$35.9 million for the thirteen weeks ended May 28, 2022 November 26, 2022. The decrease Net income benefited by higher gross profit, higher interest income, and lower interest expense, partially offset by growth in net income was partially driven by a \$1.1 million decrease in income from operations, unfavorable effects of marketing expenses, higher raw material and co-manufacturing stock based compensation expenses, executive transition costs, and supply chain challenges, and the \$2.8 million increase in interest expense in the thirteen weeks ended May 27, 2023 as discussed above. higher income tax expense.

Adjusted EBITDA. Adjusted EBITDA increased \$3.3 million \$1.2 million, or 5.3% 2.0% for the thirteen weeks ended May 27, 2023 November 25, 2023 compared to the thirteen weeks ended May 28, 2022 November 26, 2022, driven primarily by higher gross profit, and lower selling and partially offset by growth in marketing spend expenses. For a reconciliation of Adjusted EBITDA to its most directly comparable GAAP measure, see "Reconciliation of EBITDA and Adjusted EBITDA" below.

Comparison of Unaudited Results for the Thirty-Nine Weeks Ended May 27, 2023 and the Thirty-Nine Weeks Ended May 28, 2022

The following unaudited table presents, for the periods indicated, selected information from our Consolidated Statements of Operations and Comprehensive Income, including information presented as a percentage of net sales:

(In thousands)	Thirty-Nine Weeks Ended		Thirty-Nine Weeks Ended	
	May 27, 2023	% of Net Sales	May 28, 2022	% of Net Sales
Net sales	\$ 922,254	100.0 %	\$ 894,514	100.0 %
Cost of goods sold	589,284	63.9 %	550,788	61.6 %
Gross profit	332,970	36.1 %	343,726	38.4 %
Operating expenses:				
Selling and marketing	88,650	9.6 %	94,816	10.6 %
General and administrative	82,085	8.9 %	76,711	8.6 %
Depreciation and amortization	13,035	1.4 %	12,966	1.4 %
Total operating expenses	183,770	19.9 %	184,493	20.6 %
Income from operations	149,200	16.2 %	159,233	17.8 %
Other income (expense):				
Interest income	660	0.1 %	1	— %
Interest expense	(23,201)	(2.5) %	(16,528)	(1.8) %
Loss in fair value change of warrant liability	—	— %	(30,062)	(3.4) %
Gain on foreign currency transactions	74	— %	503	0.1 %
Other income	10	— %	26	— %
Total other expense	(22,457)	(2.4) %	(46,060)	(5.1) %
Income before income taxes	126,743	13.7 %	113,173	12.7 %
Income tax expense	29,810	3.2 %	34,726	3.9 %
Net income	\$ 96,933	10.5 %	\$ 78,447	8.8 %
Other financial data:				
Adjusted EBITDA ⁽¹⁾	\$ 178,301	19.3 %	\$ 183,086	20.5 %

⁽¹⁾ Adjusted EBITDA is a non-GAAP financial metric. See "Reconciliation of EBITDA and Adjusted EBITDA" below for a reconciliation of net income to EBITDA and Adjusted EBITDA for each applicable period.

Net sales. Net sales of \$922.3 million represented an increase of \$27.7 million, or 3.1%, for the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022. The increase was primarily attributable to the price increase effective in the fourth quarter of fiscal year 2022, which drove the 3.5% increase in our North America net sales in the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022. The increase in North America net sales was partially offset by a 8.9% decline in our international business and a 0.8% headwind to net sales growth related to our shift from direct sales to licensing the Quest® frozen pizza business in the third quarter of fiscal year 2022.

Cost of goods sold. Cost of goods sold increased \$38.5 million, or 7.0%, for the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022. The cost of goods sold increase was primarily driven by higher raw material, packaging, and co-manufacturing costs and supply chain challenges in the thirty-nine weeks ended May 27, 2023.

Gross profit. Gross profit decreased \$10.8 million, or 3.1%, for the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022. Additionally, gross profit of \$333.0 million, or 36.1% of net sales, for the thirty-nine weeks ended May 27, 2023 decreased 230 basis points from 38.4% of net sales for the thirty-nine weeks ended May 28, 2022. The decreases in gross profit and gross profit margin were primarily driven by the unfavorable effects of higher raw material, packaging, and co-manufacturing

costs and supply chain challenges in the thirty-nine weeks ended May 27, 2023 as previously discussed. These decreases were partially offset by the favorable effects of the price increase which became effective in the fourth quarter of fiscal year 2022.

Operating expenses. Operating expenses decreased \$0.7 million, or 0.4%, for the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022 due to the following:

- **Selling and marketing.** Selling and marketing expenses decreased \$6.2 million, or 6.5%, for the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022, primarily related to the timing of marketing spend.
- **General and administrative.** General and administrative expenses increased \$5.4 million, or 7.0%, for the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022. The increase in general and administrative expense was primarily attributable to a \$1.8 million increase in stock-based compensation, \$1.2 million of executive officer transition costs, increased general corporate costs and increased plant trial spend in the thirty-nine weeks ended May 27, 2023. These increases were partially offset by the discontinuation of costs related to business integration activities and restructuring charges of \$0.6 million and a reduction in employee-related expenses in the thirty-nine weeks ended May 28, 2022.
- **Depreciation and amortization.** Depreciation and amortization expenses were \$13.0 million and \$13.0 million for the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022, respectively.

Interest expense. Interest expense increased \$6.7 million for the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022, primarily due to the increase in interest rates on our Term Facility (as defined below) to 7.7% as of May 27, 2023 from 4.7% as of May 28, 2022. Interest expense related to the amortization of deferred financing costs and debt discount decreased \$0.1 million for the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022.

Loss in fair value change of warrant liability. There were no outstanding liability-classified Private Warrants during the thirty-nine weeks ended May 27, 2023. During the thirty-nine weeks ended May 28, 2022, we recorded a non-cash loss of \$30.1 million related to changes in valuation of our Private Warrants, which was primarily driven by movements in our stock price. On January 7, 2022, the Private Warrants were exercised on a cashless basis, resulting in a net issuance of 4,830,761 shares of common stock.

Gain on foreign currency transactions. Foreign currency transactions resulted in a gain of \$0.1 million and a gain of \$0.5 million for the thirty-nine weeks ended May 27, 2023 and May 28, 2022, respectively. During the thirty-nine weeks ended, we recognized a foreign currency translation gain of \$1.1 million related to the liquidation of a foreign subsidiary. The remaining variance is attributable to changes in foreign currency rates related to our international operations.

Income tax expense. Income tax expense decreased \$4.9 million for the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022. The decrease in our income tax expense is primarily driven by lower income from operations and changes in permanent differences.

Net income. Net income was \$96.9 million for the thirty-nine weeks ended May 27, 2023, an increase of \$18.5 million compared to net income of \$78.4 million for the thirty-nine weeks ended May 28, 2022. The increase was primarily driven by the \$30.1 million non-cash fair value loss incurred in the thirty-nine weeks ended May 28, 2022 related to the measurement of our liability-classified Private Warrants. The increase was partially offset by a \$10.0 million decrease in income from operations driven by the unfavorable effects of higher raw material and co-manufacturing costs and supply chain challenges, and higher interest costs associated with long-term debt in the thirty-nine weeks ended May 27, 2023 as discussed above.

Adjusted EBITDA. Adjusted EBITDA decreased \$4.8 million, or 2.6% for the thirty-nine weeks ended May 27, 2023 compared to the thirty-nine weeks ended May 28, 2022, driven primarily by better than expected net sales and lower SG&A costs. For a reconciliation of Adjusted EBITDA to its most directly comparable GAAP measure, see "Reconciliation of EBITDA and Adjusted EBITDA" below.

Reconciliation of EBITDA and Adjusted EBITDA

EBITDA and Adjusted EBITDA are non-GAAP financial measures commonly used in our industry and should not be construed as alternatives to net income as an indicator of operating performance or as alternatives to cash flow provided by operating activities as a measure of liquidity (each as determined in accordance with GAAP). The Company defines EBITDA as net income or loss before interest income, interest expense, income tax expense, depreciation and amortization, and Adjusted EBITDA as further adjusted to exclude the following items: stock-based compensation expense, executive transition costs, integration costs, restructuring costs, loss in fair value change of warrant liability, term loan transaction fees, and other non-core expenses. The Company believes that EBITDA and Adjusted EBITDA, when used in conjunction with net income, are useful to provide additional information to investors. Management of the Company uses EBITDA and Adjusted EBITDA to supplement net income because these measures reflect operating results of the on-going operations, eliminate items that are not directly attributable to the Company's underlying operating performance, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to the key metrics the Company's management uses in its financial and operational decision making. The Company also believes that EBITDA and Adjusted EBITDA are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in its industry. EBITDA and Adjusted EBITDA may not be comparable to other similarly titled captions of other companies due to differences in the non-GAAP calculation.

The following unaudited table provides a reconciliation of EBITDA and Adjusted EBITDA to its most directly comparable GAAP measure, which is net income, for the thirteen and thirty-nine weeks ended May 27, 2023 November 25, 2023 and May 28, 2022 November 26, 2022:

(In thousands)	(In thousands)	Thirteen Weeks Ended		Thirty-Nine Weeks Ended		(In thousands)	Thirteen Weeks Ended	
		May 27, 2023	May 28, 2022	May 27, 2023	May 28, 2022		November 25, 2023	November 26, 2022
Net income	Net income	\$ 35,431	\$ 38,834	\$ 96,933	\$ 78,447	Net income	\$ 35,561	\$ 35,860
Interest income	Interest income	(407)	—	(660)	(1)	Interest income	(1,090)	(7)
Interest expense	Interest expense	7,649	4,881	23,201	16,528	Interest expense	6,034	7,055
Income tax expense	Income tax expense	11,716	11,654	29,810	34,726	Income tax expense	11,547	9,696
Depreciation and amortization	Depreciation and amortization	5,140	4,826	15,044	14,398	Depreciation and amortization	5,605	4,952
EBITDA	EBITDA	59,529	60,195	164,328	144,098	EBITDA	57,657	57,556
Stock-based compensation expense	Stock-based compensation expense	4,124	2,994	10,456	8,691	Stock-based compensation expense	4,168	3,313
Executive transition costs	Executive transition costs	737	—	1,158	—	Executive transition costs	366	—
Integration of Quest		—	175	—	468			
Restructuring		—	—	—	98			
Loss in fair value change of warrant liability		—	—	—	30,062			
Term loan transaction fees		2,423	—	2,423	—			
Other ⁽¹⁾	Other ⁽¹⁾	(178)	(73)	(64)	(331)	Other ⁽¹⁾	(226)	(103)
Adjusted EBITDA	Adjusted EBITDA	\$ 66,635	\$ 63,291	\$ 178,301	\$ 183,086	Adjusted EBITDA	\$ 61,965	\$ 60,766

⁽¹⁾ Other items consist principally of exchange impact of foreign currency transactions and other expenses.

Liquidity and Capital Resources

Overview

We have historically funded our operations with cash flow from operations and, when needed, with borrowings under our Credit Agreement (as defined below). Our principal uses of cash have been working capital, debt service, repurchases of our common stock, and acquisition opportunities.

We had \$68.8 million \$121.4 million in cash as of May 27, 2023 November 25, 2023. We believe our sources of liquidity and capital will be sufficient to finance our continued operations, growth strategy and additional expenses we expect to incur for at least the next twelve months. As circumstances warrant, we may issue debt and/or equity securities from time to time on an opportunistic basis, dependent upon market conditions and available pricing. We make no assurance that we can issue and sell such securities on acceptable terms or at all.

Our material future cash requirements from contractual and other obligations relate primarily to our principal and interest payments for our Term Facility, as defined and discussed below, and our operating and finance leases. Refer to Note 5, Long-Term Debt and Line of Credit, and Note 8, Leases, of the Notes to Unaudited Consolidated Financial Statements in this Report for additional information related to the expected timing and amount of payments related to our contractual and other obligations.

Debt and Credit Facilities

On July 7, 2017, we (through certain of our subsidiaries) entered into a credit agreement with Barclays Bank PLC and other parties (as amended to date, the "Credit Agreement"). The Credit Agreement at that time provided for (i) a term facility of \$200.0 million ("Term Facility") with a seven-year maturity and (ii) a revolving credit facility of up to \$75.0 million (the "Revolving Credit Facility") with a five-year maturity. Substantially concurrent with the consummation of the business combination which formed the Company between Conyers Park Acquisition Corp. and NCP-ATK Holdings, Inc. on July 7, 2017, the full \$200.0 million of the Term Facility (the "Term Loan") was drawn.

On November 7, 2019, we entered into a second amendment (the "Incremental Facility Amendment") to the Credit Agreement to increase the principal borrowed on the Term Facility by \$460.0 million. The Term Facility together with the incremental borrowing make up the Initial Term Loans (as defined in the Incremental Facility Amendment). The Incremental Facility Amendment was executed to partially finance the acquisition of Quest Nutrition, LLC on November 7, 2019. No amounts under the Term Facility were repaid as a result of the execution of the Incremental Facility Amendment.

Effective as of December 16, 2021, we entered into a third amendment (the "Extension Amendment") to the Credit Agreement. The Extension Amendment provided for an extension of the stated maturity date of the Revolving Commitments and Revolving Loans (each as defined in the Credit Agreement) from July 7, 2022 to the earlier of (i) 91 days prior to the then-effective maturity date of the Initial Term Loans and (ii) December 16, 2026.

On January 21, 2022, the Company entered into the "2022 Repricing Amendment" to the Credit Agreement. The 2022 Repricing Amendment, among other things, (i) reduced the interest rate per annum applicable to the Initial Term Loans outstanding under the Credit Agreement immediately prior to the effective date of the 2022 Repricing Amendment, (ii) reset the prepayment premium for the existing Initial Term Loans to apply to Repricing Transactions (as defined in the Credit Agreement) that occur within six months after the effective date of the 2022 Repricing Amendment, and (iii) implemented SOFR and related replacement provisions for LIBOR.

On April 25, 2023, the Company entered into the “2023 Repricing Amendment” to the Credit Agreement. The 2023 Repricing Amendment, (i) reduced the interest rate per annum applicable to the Initial Term Loans outstanding under the Credit Agreement immediately prior to April 25, 2023, and (ii) provided for an extension of the maturity date of the Initial Term Loans from July 7, 2024, to March 17, 2027.

The 2023 Repricing Amendment did not change the interest rate on the Revolving Credit Facility, which continues to bear interest based upon the Company's consolidated net leverage ratio as of the end of the fiscal quarter for which consolidated financial statements are delivered to the Administrative Agent under the Credit Agreement. No additional debt was incurred, or any proceeds received by the Company in connection with the 2023 Repricing Amendment. No amounts under the Term Facility were repaid as a result of the execution of the 2023 Repricing Amendment.

Effective as of the 2023 Repricing Amendment, the interest rate per annum for the Initial Term Loans is based on either:

- i. A base rate equaling the higher of (a) the “prime rate,” (b) the federal funds effective rate plus 0.50%, or (c) the Adjusted Term SOFR Rate (as defined in the Credit Agreement) applicable for an interest period of one month plus 1.00% plus (x) 1.50% margin for the Term Loan or (y) 2.00% margin for the Revolving Credit Facility; or
- ii. SOFR plus a credit spread adjustment equal to 0.10% for one-month SOFR, 0.15% for up to three-month SOFR and 0.25% for up to six-month SOFR, subject to a floor of 0.50%, plus (x) 2.50% margin for the Term Loan or (y) 3.00% margin for the Revolving Credit Facility.

In connection with the closing of the 2023 Repricing Amendment, the Company expensed \$2.4 million primarily for third-party fees and capitalized an additional \$2.7 million primarily for the payment of upfront lender fees (original issue discount).

The Simply Good Foods Company is not a borrower under the Credit Agreement and has not provided a guarantee of the Credit Agreement. Simply Good Foods USA, Inc., is the administrative borrower and certain other subsidiary holding companies are co-borrowers under the Credit Agreement. Each of the Company's domestic subsidiaries that is not a named borrower under the Credit Agreement has provided a guarantee on a secured basis. As security for the payment or performance of the debt under the Credit Agreement, the borrowers and the guarantors have pledged certain equity interests in their respective subsidiaries and granted the lenders a security interest in substantially all of their domestic assets. All guarantors other than Quest Nutrition, LLC are holding companies with no assets other than their investments in their respective subsidiaries.

The Credit Agreement contains certain financial and other covenants that limit the Company's ability to, among other things, incur and/or undertake asset sales and other dispositions, liens, indebtedness, certain acquisitions and investments, consolidations, mergers, reorganizations and other fundamental changes, payment of dividends and other distributions to equity and warrant holders, and prepayments of material subordinated debt, in each case, subject to customary exceptions materially consistent with credit facilities of such type and size. The Revolving Credit Facility has a maximum total net leverage ratio equal to or less than 6.00:1.00 contingent on credit extensions in excess of 30% of the total amount of commitments available under the Revolving Credit Facility. Any failure to comply with the restrictions of the credit facilities may result in an event of default. The Company was in compliance with all covenants as of **May 27, 2023** **November 25, 2023** and **August 27, 2022** **August 26, 2023**, respectively.

At **May 27, 2023** **November 25, 2023**, the outstanding balance of the Term Facility was **\$325.0 million** **\$275.0 million**. We are not required to make principal payments on the Term Facility over the twelve months following the period ended **May 27, 2023** **November 25, 2023**. The outstanding balance of the Term Facility is due upon its maturity in March 2027. As of **May 27, 2023** **November 25, 2023**, there were no amounts drawn against the Revolving Credit Facility.

Stock Repurchase Program

On October 21, 2022, we announced that our Board of Directors had approved the addition of \$50.0 million to our stock repurchase program, resulting in authorized stock repurchases of up to an aggregate of \$150.0 million. The Company did not repurchase any shares of common stock during the thirteen weeks ended **May 27, 2023** **November 25, 2023**. During the **thirty-nine** **thirteen** weeks ended **May 27, 2023** **November 26, 2022**, the Company repurchased 546,346 shares of common stock at an average share price of \$30.11 per share. During the thirteen weeks ended May 28, 2022, the Company repurchased 218,221 shares of common stock at an average share price of \$37.16 per share. During the **thirty-nine** weeks ended May 28, 2022, the Company repurchased 789,742 shares of common stock at an average share price of \$36.09 per share.

As of **May 27, 2023** **November 25, 2023**, approximately \$71.5 million remained available for repurchases under our \$150.0 million stock repurchase program. Refer to Note 10, Stockholders' Equity, of the Notes to Unaudited Consolidated Financial Statements in this Report for additional information related to our stock repurchase program.

Cash Flows

The following table sets forth the major sources and uses of cash for each of the periods set forth below (in thousands):

		Thirty-Nine Weeks Ended		Thirteen Weeks Ended	
		May 27, 2023	May 28, 2022	November 25, 2023	November 26, 2022
Net cash provided by operating activities	Net cash provided by operating activities	\$ 110,412	\$ 67,363	\$ 47,523	\$ 8,718
Net cash used in investing activities	Net cash used in investing activities	\$ (10,446)	\$ (7,283)	\$ (800)	\$ (1,238)
Net cash used in financing activities	Net cash used in financing activities	\$ (98,579)	\$ (78,476)	\$ (13,103)	\$ (20,761)

Operating activities. Our net cash provided by operating activities increased **\$43.0 million** **\$38.8 million** to **\$110.4 million** **\$47.5 million** for the **thirty-nine** **thirteen** weeks ended **May 27, 2023** **November 25, 2023** compared to **\$67.4 million** **\$8.7 million** for the **thirty-nine** **thirteen** weeks ended **May 28, 2022** **November 26, 2022**. The increase in cash provided by operating activities was primarily attributable to the **\$23.9 million** decrease in cash paid for taxes, and changes in working capital for the **thirty-nine** **thirteen** weeks ended **May 27, 2023** **November 25, 2023** as compared to the **thirty-nine** **thirteen** weeks ended **May 28, 2022** **November 26, 2022**. Changes in working capital, comprised of changes in accounts

receivable, net, inventories, prepaid expenses, accounts payable, and accrued expenses and other current liabilities, which are driven by the timing of payments and receipts and seasonal building of inventory, consumed cash of \$25.8 million \$7.7 million in the thirty-nine thirteen weeks ended May 27, 2023 November 25, 2023 compared to \$44.2 million \$47.6 million of cash consumed in the thirty-nine thirteen weeks ended May 28, 2022 November 26, 2022. These increases in cash provided by operating activities were partially offset by the \$10.0 million \$0.7 million decrease in income from operations to \$149.2 \$51.8 million for the thirteen weeks ended November 25, 2023 as compared to \$52.5 million for the thirteen weeks ended November 26, 2022. Additionally, cash paid for interest was \$2.1 million

[Table of Contents](#)

million for in the thirty-nine thirteen weeks ended May 27, 2023 as compared to \$159.2 million for the thirty-nine weeks ended May 28, 2022, primarily driven by the unfavorable effects of higher raw material and co-manufacturing costs and supply chain challenges as discussed in "Results of Operations" above. Additionally, cash paid for interest was \$21.3 million in the thirty-nine weeks ended May 27, 2023 November 25, 2023, which was an increase a decrease of \$7.0 million \$4.3 million as compared to the \$14.3 million \$6.4 million paid for interest in the thirty-nine thirteen weeks ended May 28, 2022 November 26, 2022. Interest income increased by \$1.0 million for the thirteen weeks ended November 25, 2023 compared to the thirteen weeks ended November 26, 2022, due to higher cash balances, the increase in interest rates, and other sources of interest income. In addition, cash paid for taxes increased \$0.6 million.

Investing activities. Our net cash used in investing activities was \$10.4 million \$0.8 million for the thirty-nine thirteen weeks ended May 27, 2023 November 25, 2023 compared to \$7.3 million \$1.2 million for the thirty-nine thirteen weeks ended May 28, 2022 November 26, 2022. Our net cash used in investing activities for the thirty-nine thirteen weeks ended May 27, 2023 November 25, 2023 primarily comprised \$10.1 million \$0.7 million of purchases of property and equipment. The \$7.3 million \$1.2 million of net cash used in investing activities for the thirty-nine thirteen weeks ended May 28, 2022 November 26, 2022 primarily comprised \$4.7 \$1.2 million of purchases of property and equipment and the issuance of a \$2.4 million note receivable. equipment.

Financing activities. Our net cash used in financing activities was \$98.6 million \$13.1 million for the thirty-nine thirteen weeks ended May 27, 2023 November 25, 2023 compared to \$78.5 million \$20.8 million for the thirty-nine thirteen weeks ended May 28, 2022 November 26, 2022. Net cash used in financing activities for the thirty-nine thirteen weeks ended May 27, 2023 November 25, 2023 primarily consisted of \$16.4 million of repurchases in common stock, \$81.5 \$10.0 million in principal payments on the Term Facility, and \$2.8 \$3.6 million in tax payments related to issuance of restricted stock units and performance stock units, partially offset by \$5.0 \$0.6 million of cash proceeds received from option exercises. the partial repayment of an outstanding note receivable. Net cash used in financing activities for the thirty-nine thirteen weeks ended May 28, 2022 November 26, 2022 primarily consisted of \$28.5 \$16.4 million in repurchases of common stock, \$50.0 \$6.5 million in principal payments on the Term Facility, and \$3.5 \$2.3 million in tax payments related to issuance of restricted stock units and performance stock units, partially offset by \$4.3 \$4.6 million of cash proceeds received from option exercises. During the thirteen weeks ended May 27, 2023, the Company extended its Term Loan maturity to March 2027 from July 2024. The Company paid \$2.7 million of incremental deferred financing fees, primarily for the payment of upfront lender fees (original issue discount), in conjunction with the term loan transaction.

New Accounting Pronouncements

For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our consolidated financial statements, refer to our Annual Report. Refer to Note 2, Summary of Significant Accounting Policies, of our unaudited interim consolidated financial statements in this Report for further information regarding recently issued accounting standards.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

There were no material changes in our market risk exposure during the thirteen week period ended May 27, 2023 November 25, 2023. We continue to expect to experience logistics challenges in our supply chain as well as on balance higher raw material, packaging, and co-manufacturing costs and supply chain challenges in fiscal year 2023. In addition, current or future governmental policies may increase the risk of inflation and possible economic recession, which could further increase the costs of ingredients, packaging and finished goods for our business as well as negatively effect consumer behavior and demand for our products. As a result, we instituted price increases effective in the first and fourth quarters of fiscal year 2022. However, there can be no assurance that the price increases will fully offset the effects of higher raw material and supply and distribution costs on our results of operations and financial condition. For a discussion of our market risks, see "Quantitative and Qualitative Disclosures About Market Risk" in Part II, Item 7A of our Annual Report.

Item 4. Controls and Procedures

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosures.

Management, including the participation of our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation (pursuant to Rule 13a-15(b) under the Exchange Act) of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of May 27, 2023 November 25, 2023, the Company's disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during the quarter ended May 27, 2023 November 25, 2023, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Inherent Limitations on Effectiveness of Controls

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Additionally, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

PART II. Other Information

Item 1. Legal Proceedings

From time to time, we have been and may again become involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any litigation that we believe to be material and we are not aware of any pending or threatened litigation against us that we believe could have a material adverse effect on our business, operating results, financial condition or cash flows.

Item 1A. Risk Factors

Readers should carefully consider the factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report, which could materially affect our business, financial condition, cash flows or future results. There have been no material changes in our risk factors included in our Annual Report. The risks described in our Annual Report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition or future results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

In the three months ended November 23, 2023, no directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits

Exhibit No.	Document
10.1	Repricing Amendment, dated as of April 25, 2023, by and among Atkins Intermediate Holdings, LLC, a Delaware limited liability company, Conyers Park Acquisition Corp., a Delaware corporation, Simply Good Foods USA, Inc., a New York corporation, Atkins Nutritional Holdings, Inc., a Delaware corporation, Atkins Nutritional Holdings II, Inc., a Delaware corporation, NCP-ATK Holdings, Inc., a Delaware corporation, the other guarantors party thereto, the financial institutions party thereto as Consenting Lenders and the Replacement Lender and Barclays Bank PLC, as administrative agent.
31.1*	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32.1**	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act.
101.INS*	XBRL Instance Document (the instance document does not appear on the Interactive Data File because the XBRL tags are embedded within the Inline XBRL document)
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).
* Filed herewith.	
** Furnished herewith.	
† Indicates a management contract or compensatory plan.	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

THE SIMPLY GOOD FOODS COMPANY

By: /s/ Timothy A. Matthews

Date: June 29, 2023 January 4,
2024

Name: Timothy A. Matthews

Title: Vice President, Controller, and Chief Accounting Officer
(Duly Authorized Officer and Principal Accounting Officer)

33 29

Exhibit 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) OF THE U.S. SECURITIES EXCHANGE ACT OF 1934 (Section 302 of the Sarbanes-Oxley Act of 2002)

I, Joseph Geoff E. Scalzo, Tanner, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of The Simply Good Foods Company (the "registrant");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

- a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 29, 2023 January 4, 2024 By: /s/ Joseph Geoff E. Scalzo Tanner
Name: Joseph Geoff E. Scalzo Tanner
Title: Chief Executive Officer, President and Director
(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION
PURSUANT TO RULES 13a-14(a) AND 15d-14(a)
OF THE U.S. SECURITIES EXCHANGE ACT OF 1934
(Section 302 of the Sarbanes-Oxley Act of 2002)

I, Shaun Mara, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of The Simply Good Foods Company (the "registrant");
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

- b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 29, 2023 January 4, 2024 By: /s/ Shaun Mara
Name: Shaun Mara
Title: Chief Financial Officer
(Principal Financial Officer)

Exhibit 32.1

**CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)**

In connection with the Quarterly Report of The Simply Good Foods Company (the "Company") on Form 10-Q for the fiscal period ended May 27, 2023 November 25, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to such officer's knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company covered by the Report.

This certificate is being furnished solely for the purposes of 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

Date: June 29, 2023 January 4, 2024 By: /s/ Joseph Geoff E. Scalzo Tanner
Name: Joseph Geoff E. Scalzo Tanner
Title: Chief Executive Officer, President and Director
(Principal Executive Officer)

Date: June 29, 2023 January 4, 2024 By: /s/ Shaun Mara
Name: Shaun Mara
Title: Chief Financial Officer
(Principal Financial Officer)

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.